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Background: The increasing consumption of dietary supplements (DS) has drawn the 
attention of regulatory agencies, researchers and healthcare professionals. The US Food 
and Drug Administration (FDA) does not require premarketing assessment of DS 
considering them safe unless proven otherwise. However, the reporting rate of DS adverse 
events (DS-AE) is low. 
 
 
 
 
Objective: To describe pharmacists’ attitudes and knowledge of DS and DS information 
resources, and to determine the importance of selected attributes in pharmacists’ decisions 
to report a DS-AE. 
 
Methods: A convenience sample of practicing pharmacists in Virginia was surveyed using 
a web-based self-administered questionnaire. A conjoint analysis exercise was developed 
using several scenarios based on a set of five attributes: patient’s age, initiation of DS, last 
modification in drug therapy, evidence supporting the AE, and outcome of the AE. 
Participants were asked to indicate their decision to report the AE in each scenario to 
prescriber, drug manufacturer, DS manufacturer and FDA on a 6-point ordered scale. 
Participants’ attitude, knowledge of DS, demographic information, and DS information 
resources were also requested. Linear regression models were used to determine the 
relative importance of the profile attributes on a pharmacist’s decision to report the AE. 
The effects of other characteristics on the importance of the attributes were assessed. 
 
Results: Participants’ overall attitudes were relatively positive for the clinical use of DS 
but negative for safe of DS. Formal training on DS was associated with better knowledge 
of DS regulation. The average knowledge score of DS identification was relatively good 
but was low for DS regulation. Lexi-Comp® was the most widely used and available 
information resource and the Natural Medicines Comprehensive Database was the most 
useful once. The most important attribute that a pharmacist considered in the decision to 
report a DS-AE to DS manufacturer, drug manufacturer and FDA was the outcome of the 
 
 
 
AE followed by the evidence supporting the AE. Ranking of these two factors was the 
reversed in reporting to prescriber. 
 
Conclusions: Outcome and evidence of the AE are the most important factors participants 
considered when reporting. Other characteristics do not have an impact on the relative 
importance of the attributes. 
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CHAPTER 1 INTRODUCTION 
 
 
 
 
Background 
 
The increasing level of consumption of DS in the U.S. in the last two decades has drawn 
the attention of regulatory agencies, researchers and healthcare professionals. The United States 
is leading the world in DS consumption across all segments of the population.1-3 Between 1999 
and 2002, approximately 57% of women and 47% of men in the U.S. reported using some type 
of DS in the past 30 days.4, 5 In addition, the market of DS is growing to be a billion dollar 
industry with sales of $23.7 billion in 2007.6 These DS include substances such as vitamins, 
minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, 
and metabolites.7 This definition is comprehensive and includes wide variety of supplements that 
are very different in their effectiveness and safety for human consumption. While some of these 
DS are effective and safe, there are many safety concerns associated with the use of some others. 
For example, Ginkgo biloba has been implicated in the occurrence of an epileptic seizure, and 
chronic use of zinc may result in anemia.8 
In addition, some potentially dangerous interactions between DS and drugs have been 
described in the literature. These interactions could be synergistic effects, poisoning, or 
inactivation of one of the substances. For instance, St. John’s Wort that is used to enhance mood 
may interact with several narrow therapeutic range drugs that are metabolized through the liver. 
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These interactions are mediated through the ability of St. John’s Wort to induce liver enzymes of 
the cytochrome P450 system. St. John’s Wort may also increase the toxicity of some 
antidepressants and compromise the effectiveness of some anticonvulsants and HIV antivirus 
drugs.9, 10 Garlic, ginger, and Ginkgo biloba may increase risk of bleeding when used with 
anticoagulants.11 
The effectiveness of many individual DS products and combination DS products is not 
known. Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, the U.S. 
Food and Drug Administration (FDA), unlike new prescription and over-the-counter drugs, does 
not require premarketing efficacy and safety assessments of DS.7, 12 Only after a DS product 
reaches the market is the FDA responsible for taking action against any product proven to be 
unsafe. It is the responsibility of the DS manufacturer to ensure the effectiveness and safety of 
their products.  DS manufacturers are, however, obligated to follow the current good 
manufacturing practices (cGMPs) for DS. These practices require proper control of DS so that 
they are processed in a consistent manner and meet quality standards.13 FDA considers DS as 
generally safe unless proven otherwise through its Adverse Event Reporting System (AERS). If 
there are signals of a health concern, FDA conduct further investigations through literature 
review, clinical data analysis, or conducting clinical studies to confirm the health concern. After 
confirmation, FDA takes safety actions including warning consumers and healthcare 
professionals, requesting recalls or even stopping the importation or manufacturing of a DS 
product.  
According to DSHEA, DS manufacturers are not required to report adverse events to 
FDA. It was not until 2006 when congress passed the Dietary Supplements and Nonprescription 
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Drug Consumer Protection Act (DSNDCPA) stating that the manufacturing party, defined as 
manufacturer, packer, distributor and retailer if appears on the label as distributer, is responsible 
for reporting all serious adverse events associated with their products to the FDA MedWatch 
system within 15 business days.12 The report must be submitted using a MedWatch form 
accompanied by a copy of the label of the marketed DS product. Additionally, healthcare 
professionals and consumers may voluntarily report serious and non-serious adverse events 
related to DS to the FDA MedWatch system.14 The literature shows that most of the time 
healthcare professionals do not seem to report adverse events related to the use of DS so a 
majority of the adverse events probably go unreported to the FDA.15 Contributing to this 
underreporting may be the assumption that most DS are considered safe by consumers and 
healthcare providers.16 Other factors that might affect healthcare professionals’ reporting patterns 
of adverse events related to the use of DS are age of the professional, years of experience, 
knowledge about DS and understanding of the reporting process of an AE.17, 18 Identifying which 
factors affect the decision to report an AE could be helpful for authorities and administrative 
personnel in developing educational programs to improve the awareness of consumers and 
healthcare professionals about regulations of DS. 
Among healthcare professionals, community pharmacists play an important role in the 
field of DS safety given the over-the-counter sale of these products in the community. They 
could be among the first line in detecting and reporting adverse events related to the use of DS. 
Moreover, DS consumers consider pharmacists as reliable and knowledgeable source of 
information and advice about DS. In a U.S. study, 37% of respondents viewed pharmacists’ 
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advice for complementary and alternative medicine (CAM) as important and 30% of them relied 
on pharmacists as a source of information about the choices of DS and herbal products.19 
Conjoint analysis (CA) and discrete choice experiments (DCE) are different methods that 
have been used to measure the importance of factors involved in making a personal judgment or 
a preference among alternatives. In the last two decades, CA has been increasingly used in 
medical research. This technique combines both experimental designs and survey designs in 
which scenarios are used to determine attributes influencing respondents’ preferences or 
decisions in performing some action. 
It is hypothesized that the decision of a pharmacist to report a DS related AE might be 
influenced by various attributes that are related to the patient, DS, concomitant drugs, severity of 
outcome, practice setting and availability of DS information resources and characteristics of 
practicing pharmacist. 
 
Objectives and Hypothesis 
 
As described in the conceptual framework in Figure 1.1, there are three objectives for this 
project: 
1. Determine the importance of selected attributes that influence a pharmacist’s 
decision to report a DS related AE. 
 
Hypothesis 1: Age of the patient is an important attribute influencing pharmacists’ 
decision to report a DS-AE. 
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Hypothesis 2: Time since initiation of dietary supplement is an important attribute 
influencing pharmacists’ decision to report a DS-AE. 
 
Hypothesis 3: Time since last change of drug therapy is an important attribute 
influencing pharmacists’ decision to a DS-AE. 
 
Hypothesis 4: Evidence of the AE in the literature is an important attribute 
influencing pharmacists’ decision to report a DS-AE. 
 
Hypothesis 5: Level of outcome of the AE is an important attribute influencing   
pharmacists’ decision to report a DS-AE. 
 
2. Describe practicing pharmacists’ attitudes toward DS, knowledge about DS and 
understanding of their regulations, practice setting 
3. Describe the availability, usage and usefulness of common DS information 
resources. 
4. Determine the effect of pharmacist’s characteristics (objective 2) on the importance 
of the selected attributes that influence a pharmacist’s decision to report a DS 
related AE (objective 1) 
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Figure 1.1 – The conceptual framework of project objectives 
 
  
 
 
Objective 1 
- Determine patient 
factors influencing 
reporting 
Objective 2 
- Pharmacist 
characteristics and 
knowledge 
- Information sources 
Objective 4 
- Determine the effect of 
Objective 2 RPh 
characteristics on 
Objective 1 factors 
Pharmacist Characteristics 
- Attitude 
- Knowledge 
- Practice setting 
- Demographics 
Objective 3 
DS Information Resources 
- Availability 
- Usage 
- Usefulness 
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Significance 
 
As mentioned before, FDA does not require premarketing safety and efficacy assessment 
of DS and considers them as generally safe unless proven otherwise through its MedWatch 
system. Unfortunately, the reporting rate of adverse events related to DS by consumers and 
healthcare professionals to the MedWatch system is low given their high consumption rate in the 
United States. Healthcare professionals should play an important role in this reporting process 
given their role in detecting and reporting of adverse events related to DS and in educating 
consumers about adverse events. Only about 20% of AERS reports were submitted by healthcare 
professionals. There are many possible factors contributing to such low reporting rate of adverse 
events related to the use of DS by healthcare professionals. Knowing which factors influence 
pharmacists’ decisions to report DS related AEs might be helpful for authorities when 
establishing policies and regulations of the reporting process for adverse events in order to 
improve the detection of safety concerns for DS. It might be helpful for administrative personnel, 
as well, when developing educational programs to improve healthcare professionals’ and 
consumers’ knowledge about DS. This study focuses on pharmacists but it could be used as a 
foundation for future studies to evaluate factors affecting other healthcare professionals in 
reporting DS related AE. 
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CHAPTER 2 LITERATURE REVIEW 
 
 
 
 
Dietary Supplements 
 
Complementary and alternative medicine (CAM) as defined by the National Institutes of 
Health (NIH) is “a group of diverse medical and health care systems, practices, and products that 
are not presently considered to be part of conventional medicine.”20 Dietary supplements (DS) 
are considered to be CAM products.  While many products fall into the DS category, the most 
commonly consumed DS are vitamins, minerals and herbals.4 The term “dietary supplement” as 
defined by Congress in the Dietary Supplement Health and Education Act (DSHEA) of 1994, is 
“a product taken by mouth to supplement the diet that contains substances like vitamins, 
minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, 
glandulars, and metabolites.” A DS is intended for ingestion by humans in the form of a capsule, 
powder, softgel, or gelcap, and not in a form of injectable products or a conventional food or 
diet.7 “Botanicals” is a synonym commonly used to refer to herbal remedies containing a plant or 
part of a plant used for its flavor, smell or therapeutic properties. The FDA regulations 
concerning DS differ from other dietary products. Before DSHEA, there was no formal 
definition of DS and the FDA had the authority to regulate them in a similar manner as diet, food 
additives or drugs.21, 22 
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Use of Dietary Supplements 
 
The prevalence of DS use varies widely. The 2002 Health and Diet Survey sponsored by 
the FDA estimated that 73% of U.S. adults aged 18 years or older who spoke English and resided 
in households with telephones used a DS in the past 12 months.3, 23 Based on National Health 
and Nutrition Examination Survey (NHANES) III database (1999-2002), about 57% of women 
and 47% of men in the U.S. reported using some type of DS in the last 30 days.4, 5 The 1999-
2002 NHANES III, showed that about 32% of children used DS regularly. A previous study 
using the 1976-1980 NHANES II indicated that the prevalence of regular use of DS among 
children varied from 42% for 1- to 2-year-old children to as low as 10% for 11- to 19-year-old 
males. Infants younger than 1 year were the lowest and 4- to 8-year-old children were the highest 
(12% and 48%, respectively).24 In a recent cross-sectional study, almost 50% of older adults 
aged 57-85 years old used at least one DS during 2005-2006.25 
Patients with various chronic diseases reported high prevalence of DS use.26, 27 About 
63% of patients with hypertension or hypercholesterolemia, 61% with coronary artery diseases 
and 53% with diabetes mellitus reported use of at least one DS in the last month.27 Among 
prescription drug users, 52% used DS concomitantly with prescription drugs.25 
The average use of DS among healthcare professionals has been suggested to be as high 
as or higher than the average use in the general population with about 81% of healthcare 
professionals enrolled in an online course reported using a vitamin, mineral, or other non-herbal 
DS and 51% of them reported using an herbal DS in the last week.28, 29 Another study showed 
that about 53% of practicing Minnesota pharmacists reported personal use of DS.16  
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Nonvitamin/nonmineral (NVNM) products are a subcategory of DS that includes amino 
acids, herbs, or other botanicals. In 2007 the National Health Interview Survey (NHIS) assessed 
the past use (in the past 12 months) and the current use (in the past 30 days) of NVNM DS. 
About 18% of adults in the U.S. said they used some type of NVNM DS in the past 12 months 
and 13% in the past month. The most commonly used NVNM DS were fish oil/omega-3 
(38.9%), glucosamine (21.9%), echinacea (17.3%), flaxseed oil or pills (15.7%), chondroitin 
(12.1%), ginseng, Ginkgo biloba, and garlic (about 11.0% each).3 The 2002 Health and Diet 
Survey estimated that 42% of U.S. adults used herbs, botanicals, or other NVNM supplement in 
the past 12 months.23 The NHIS estimated the use of NVNM in U.S. adults during 2000 to be 
about 15% at any time in the past year and 6% daily at the time of the survey. The most 
commonly used NVNM DS in this NHIS study were echinacea (30.3%), Ginkgo biloba (23.2%), 
garlic pills (15.7%) and ginseng (15.7%).1 In 2000, the prevalence of use of NVNM was 
estimated by the National Center for Health Statistics of the Centers for Disease Control and 
Prevention to be 14.5% in the past year and 6.0%in every day.1 
After the enactment of DSHEA in 1994, the estimated sales of DS including herbal 
products in the U.S. was $8.8 billion and increased to $15.7 billion in 2000.30 According to a 
2009 report of the U.S. Government Accountability Office (GAO), total estimated DS sales 
increased from 14 billion in 1997 to 23.7 billion in 2007, as shown in Figure 2.1. 6 
 
 
 
11 
 
 
 
Figure 2.1 – Total Sales of DS in the U.S. from 1997 through 2007. (reference 6) 
 
 
 
 
 
 
 
Regulations of Dietary Supplements 
 
Regulation of DS passed several events overtime as listed in Table 2.1. In 1994, the U.S. 
Congress passed the Dietary Supplement Health and Education Act (DSHEA). Before DSHEA, 
FDA has the authority to regulate DS as food additives and drugs. With that, FDA could require 
DS manufacture to provide evidence of safety and efficacy of their products before it reach the 
market. However, that could have greatly reduced consumer access to potentially beneficial DS 
products. To allow a greater access, DSHEA was passed with clear definition of DS that 
distinguished them from food additives and drugs.22 
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Under DSHEA, FDA does not require safety and effectiveness approval of DS product 
before being marketed to consumers as it does for drugs. If the DS product contains a “new 
dietary ingredient” (NDI), an ingredient that was not marketed in the U.S. before October 15, 
1994, the manufacturer may be required to notify FDA at least 75 days before marketing the 
product, depending on the history of use of the new ingredient.7, 12 DSHEA also requires that 
certain information appear on DS labels in "Supplement Facts" panel. A structure-function 
disclaimer must be on DS labels that make structure-function claims such as “Calcium builds 
strong bones”. The disclaimer says: “This statement has not been evaluated by the FDA. This 
product is not intended to diagnose, treat, cure, or prevent any disease”. The FDA neither 
approves DS products nor conducts investigations to ensure the safety and effectiveness of these 
products before they are sold to consumers. This responsibility is placed on the DS 
manufacturers; however, the FDA still has the authority to regulate and even ban a DS product 
from the market when FDA demonstrates a significant or unreasonable risk associated with the 
use of the product through its MedWatch surveillance system. For instance, the FDA issued a 
regulation that banned the sale of ephedra in 2004 due to unreasonable risk associated with the 
regular use of ephedra.31 
In 2006, significant changes have occurred in the regulation of DS. In December 2006, 
the congress passed the Dietary Supplement and Nonprescription Drug Consumer Protection Act 
(DSNDCPA) that required manufacturers to submit reports of serious AE to the FDA MedWatch 
system within 15 business days. This act became effective in December 2007.12 A serious 
adverse event, as defined in the act, included any health-related event that resulted in, for 
example, a death, life-threatening experience, inpatient hospitalization, birth defect, or which 
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required, based on reasonable medical judgment, a medical or surgical intervention to prevent 
these serious outcomes. Moderate or mild adverse events are not required to be reported to the 
FDA.12, 32 
In June 2007, FDA established its Current Good Manufacturing Practices (cGMPs) for 
DS. These manufacturing practices provide guidance for DS manufacturers to ensure DS product 
quality and consistency to meet quality standards. The cGMPs apply to all domestic and foreign 
companies and require DS to be manufactured with consistent identity, purity, strength, and 
composition. The final rule of cGMPs became effective in June 2008.13 
The Center for Food Safety and Applied Nutrition (CFSAN) in FDA was established 
after passing the Dietary Supplement and DSNDCPA with a major responsibility of ensuring that 
consumption of food and DS is safe to humans. This center monitors post-marketing safety of 
DS through voluntary DS adverse event reporting system. In addition, it monitors DS product 
information such as labeling, claims, and package inserts.33  
DSHEA also requires the formation of an executive level Commission on Dietary 
Supplement Labels and an Oﬃce of Dietary Supplements (ODS) within the National Institutes of 
Health (NIH). The Federal Trade Commission regulates any type of advertising and marketing of 
DS on television, in print, or on the Internet, to ensure that false claims are not made.34 In 2002, 
34 commercial websites of herbal supplements that are used for cancer were evaluated to 
determine the degree of compliance with the DSHEA regulation of structure/function claims. 
The study reported that 92%, 89%, and 58% of these commercial websites discussed prevention, 
treatment, and cure of cancer, respectively. The majority of websites claiming cures for cancer 
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through herb use supplied no evidence to support these claims. Fewer than 40% recommended 
that consumers consult a doctor prior to their use of DS.35 
DSHEA established the ODS in 1995 to strengthen knowledge and understanding of DS 
by evaluating scientific information, funding and supporting research, publishing research 
findings, and educating the consumers and healthcare providers about DS to ensure safely and 
enhance health for public.36 
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Table 2.1 - Key events in the regulation of dietary supplements 
 
Event Key event 
1990 The Nutrition Labeling and Education Act of 1990 amended the Federal 
Food, Drug, and Cosmetic Act to require most foods, including dietary 
supplements to bear nutrition labeling. 
1994 DSHEA amended the Federal Food, Drug, and Cosmetic Act to create a 
new regulatory, safety standard, labeling requirements, and other rules for 
dietary supplements. Under DSHEA, dietary supplements are generally 
presumed to be safe. 
2002 The Public Health Security and Bioterrorism Preparedness and Response 
Act of 2002 amended the Federal Food, Drug, and Cosmetics Act to require 
all food companies, including dietary supplements companies, to register 
with the FDA no later than December 12, 2003, to provide information on 
the name and address of the facility and, to some extent, the types of 
products they manufacture or sell. 
2004 FDA was successful in banning ephedra after thousands of adverse events, 
including a number of deaths, and a lengthy legal process. 
2006 The Dietary Supplement and Nonprescription Drug Consumer Protection 
Act amended the Federal Food, Drug, and Cosmetic Act to require dietary 
supplement companies that receive a serious adverse event report to submit 
information about the event to FDA 
2007 FDA finalized its Current Good Manufacturing Practices regulations to 
establish quality control standards for dietary supplements. The final rule 
becomes effective on August 24, 2007, but companies have 10, 22, or 34 
months from the effective date of the rule to comply, depending on 
company size. 
2007 Serious adverse event reporting requirement for dietary supplement 
companies become effective on December 22. 
Source: Adopted from reference 6 
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Safety and Efficacy of Dietary Supplements 
 
The historical use of DS and herbals was considered as proof of safety of these products 
by some manufacturers and consumers. This assumption, however, is problematic considering 
the wide variability in the concentration of the active ingredients of these products, the hundreds 
of new products, the differences in the methods of preparations, and the lack of scientific 
evidence supporting their safety for human consumption. Relatively few products and health 
claims of DS have been demonstrated, in animal or human research, to be effective and safe. For 
instance, folic acid has been shown to be effective in preventing the certain birth defects.37 Also, 
calcium and vitamin D supplements have been shown to be helpful in preventing and treating 
bone loss and osteoporosis.38  
Despite the safe use of a certain DS in the past, there is a still potential risk of using DS. 
Mega dosing of even safe DS such as vitamins and minerals might result in direct toxicity to 
consumers. For instance, excessive use of calcium might lead to complication of kidney function 
and kidney stone formation. Excessive use of vitamin A intake has been linked to liver 
abnormalities and some central nervous system adverse effects.39  
Contamination with toxins and carcinogens is another safety concern in some DS 
products. For example, in 1990 a combination product to promote sleep containing L-tryptophan 
(LT) was associated with epidemic potentially fatal eosinophilia-myalgia syndrome (EMS). This 
condition was defined the Centers for Disease Control (CDC) Morbidity and Mortality Weekly 
Report (MMWR) as a flu like condition associated with eosinophil (EOS) count ≥2000 cells/cm. 
(normal range is 50-250 cells/cm.). The association between LT and EMS was first described in 
1989 when the New Mexico Department of Health and Environment (NMDHE) received data 
 
 
17 
 
concerning three women who were consuming LT and were experiencing severe myalgia and 
eosinophilia. Many people had EMS over the next few years and by August 1990 more than 
1500 cases of EMS and 37 deaths were reported to the CDC. The explanation of this association 
was not clear. Several studies by CDC linked that to a contaminant occurring in LT batches at a 
manufacturing plant in Japan between October 1988 and June 1989. More than 60 different 
impurities that had been associated with cases of EMS were identified in the LT batches. In 
1990, LT was banned from sale in the U.S.40 Several Asian studies showed that about 20% of 
natural products in a random sample of hospitals were contaminated pharmaceutical including 
adulterants, caffeine, paracetamol, indomethacin, hydrochlorothiazide and prednisolone.41 
The FDA banned the sale of ephedrine fat-burning products in 2003, because studies 
demonstrated that use of such product was associated with increased risk of heart palpitations, 
hypertension, and stroke.42, 43 In May 2009, the FDA banned the sale of Hydroxycut, a product 
used to help burn fat, because its use was associated with nausea, vomiting, and liver injury. 
 
Dietary Supplement-Drug Interactions 
 
A recent survey found that about 31% of respondents reported taking herbal products 
with prescription drugs and 30% took DS with over the counter (OTC) drugs.44 The interactions 
between DS and drugs, both prescription and OTC, could be potentially serious, especially 
among elderly. Several studies have identified potentially dangerous interactions between DS 
and drugs. That could be synergistic, poisoning, or antagonistic effects. In a Canadian study, 
20% of children concurrently used conventional medications and natural health products (NHP). 
Theoretically possible NHP-drug or NHP-NHP interactions in the past 3 months were identified 
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in 16% children. Although many of the NHP-drug potential interactions are theoretical, few are 
as serious and potentially life threatening such as the interaction of warfarin and St. John’s wort 
that is might result in potential bleeding.45 St. John’s wort, also, has been shown to reduce 
plasma levels of some drugs like cyclosporine, warfarin, and some statins.46, 47 DS products often 
contain more than one ingredient that might interact with each other and might lead to severe 
adverse events.48 A study by NIH showed that using St. John’s Wort to enhance mood could 
significantly compromise the effectiveness of indinavir, which is an antiviral drugs often 
prescribed to treat HIV infection.9, 11 
 
Patient Disclosure of DS Use Information 
 
Disclosure of DS use to healthcare providers and factors influencing the disclosure is not 
well assessed. It is suggested that only 23% to 37% of CAM users disclosed at least one type of 
CAM use to their physician.49, 50 For example, 69% of patients who use DS and prescription 
medication concomitantly do not disclose this information to their healthcare 
providers.51Although patients may not be forthcoming about DS use, healthcare practitioners 
similarly may not be asking about such use.  Even when they do ask, patients may fail to inform 
them. A review study shows that about 70% of surgery patients who were taking DS failed to tell 
their doctors when asked.49 In a recent study that assessed the changes in herb and DS use in the 
U.S. adult population between 2002 and 2007 using National Health Interview Surveys only 
33.4% in 2002 and 45.4% in 2007 disclosed their herb or DS use to their healthcare 
professionals.3 
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Misperceptions about DS Regulations 
 
Although the DSHEA has been in place for more than 18 years, research shows that 
consumers and healthcare professionals do not understand how DS are regulated. About 1,400 
adults in the U.S. who had ever made a serious weight loss attempt were asked whether they 
believed weight loss DS were approved for safety by a government agency such as the FDA. 
More than half mistakenly reported that such DS were approved for safety by some government 
agency. The results were the same of those who used DS for weight loss and those who did not.52 
In another study, the knowledge about the FDA's role in regulating of DS was assessed on a 
convenience sample 262 of undergraduate students. The average score of a 12-item knowledge 
test was about 50%. The items were scored as 1 (True) or 0 (False).53 In a recent study by the 
same team using the same instrument, undergraduate students were randomly assigned to one of 
three experimental conditions: the description of the DS stated that it had been approved by FDA 
in the first group, the description stated that it had not been approved by FDA in the second 
group, and nothing about FDA approval was included in the description in the third group. The 
average score of a 12-item knowledge test was about 50% in all of the three groups.21 
Similar to consumers, healthcare professionals’ knowledge about DS regulations is poor. 
The average baseline knowledge score about DS regulations of 335 physicians was 59% using a 
5-item quiz as part of the study questionnaire. The average score dramatically improved after 
completion of an online learning module about DS to be 91%.54 Kemper et al. administered a 28-
item knowledge questionnaire to 1,268 healthcare professionals including physicians, nurses, 
dietitians, pharmacists, and students. The questions included items about the use, safety, and 
regulations of certain DS. The overall average score was about 66%. The average score was 
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significantly different when sub-classified by profession [(70%, 65%, 68%, 71%, and 61%; 
respectively); p <0.001].55 
 
Dietary Supplement Information Resources 
 
There are numerous information sources that healthcare professionals can consult to get 
information about DS. Access to these resources and reliability of the information is essential to 
provide informed advice to patients. These resources vary in their usefulness, ease of use, format, 
and frequency of update. These references include the Natural Medicines Comprehensive 
Database, Natural Standard (Natural Standard, Inc.), Review of Natural Products (a component 
of Facts and Comparisons 4.0), PDR for Herbal Medicines, and the web site of the National 
Center for Complementary and Alternative Medicine. Most of these resources have been 
reviewed in the literature.56-62 None of these references are comprehensive and always up-to-
date, and each of these has advantages and disadvantages. For these reasons, having access to 
more than one database or reference is important. 
Nathan et al. surveyed 64 community pharmacists to examine the availability of 
information sources in the community pharmacy setting and to assess the attitudes of community 
pharmacists toward these resources. The frequency of use of these resources to answer questions 
was mainly seldom (48.4%) or often (n = 24; 37.5%). Few of them never used (n = 5; 7.8%) or 
always use (n = 4; 6.3%) these references. The most commonly available resources were the 
PDR for Herbal Medicines (42.5%), The Review of Natural Products (20.0%), and the web site 
of the National Center for Complementary and Alternative Medicine (12.5%). Respondents were 
mainly completely satisfied or somewhat satisfied (14% and 46.3% respectively).61 
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Out of the 116 poison information centers in the Untied Stated, 66 responded to a survey 
to assess the resources these centers are using to respond to DS information requests. The most 
commonly available DS resources were Facts and Comparisons' The Review of Natural Products 
(78.80%), the print version of Natural Medicines Comprehensive Database (78.80%), and 
Complete German Commission E Monographs (69.70%). Table 2.2 list the 10 most commonly 
available resources. The most commonly used DS resources were Web site of the National 
Center for Complementary and Alternative Medicine (36.40%), AltMedDex System (16.70%), 
The Review of Natural Products (16.70%). Table 2.3 list the 10 most commonly used 
resources.62 
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Table 2.2 – Most commonly available dietary supplement resources at 66 drug information 
centers 
 
Resource Availability % 
The Review of Natural Products 78.8 
Natural Medicines Comprehensive Database (print) 78.8 
Complete German Commission E Monographs 69.7 
PDR for Herbal Medicines 66.7 
AltMedDex System 59.1 
PDR for Nonprescription Drugs and Dietary Supplements 56.1 
Tyler’s Honest Herbal 51.5 
Natural Medicines Comprehensive Database Web site 48.5 
Herbs of Choice 37.9 
PDR for Nutritional Supplements 30.3 
Source: Adapted from reference 62. 
 
 
 
 
Table 2.3 – Most commonly used dietary supplement resources at 66 drug information 
centers 
 
Resource Availability % 
Natural Medicines Comprehensive Database (print) 36.4 
AltMedDex System 16.7 
The Review of Natural Products 16.7 
Natural Medicines Comprehensive Database (print) 15.2 
Professional’s Handbook of Complementary and Alternative 
Medicine 3.0 
Complete German Commission E Monographs 1.5 
Other 1.5 
Source: Adapted from reference 62. 
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Another study assessed the usefulness of 14 most common DS references that healthcare 
professionals use to answer DS related questions. The ability of references to answer all DS 
information requests that were submitted to participating drug information centers between April 
and September 2000 were scored on a 4-point scale. The most useful electronic references for 
providing information on DS were the Natural Medicine Comprehensive Database, Micromedex 
and The Natural Pharmacist website. The Natural Therapeutics Pocket Guide was the most 
helpful book reference.57 
 
Consumers’ Sources of Information and Advice about DS 
 
Consumers of DS reported using a variety of information sources to gain knowledge of 
DS and to make their decision to use these products mostly without knowing the credibility and 
reliability of the information. These sources include healthcare providers, friends, media, and 
manufacturers of DS. Trained health professionals are not always the source of information that 
consumers use to start taking a DS.  
A study measured the prevalence of herbal (non-vitamins/non-minerals) DS usage among 
university students, rationale for usage, and identified sources of DS information. About 26% of 
student reported previous use of herbal DS. The main source of information was friends and 
family (52%), followed by health food stores (43%), and magazines and newspapers (32%). 
Mostly reported reasons of use were to improve energy (61%), to promote weight loss (38.0%), 
to burn fat (36%), and inadequate diet (35%). 
Herbold et al. surveyed a sample of athletic high school students to measure prevalence 
of DS usage, attitudes, sources of dietary supplement information, and physical activity. Of the 
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351 adolescents who completed the survey, 78% have used some type of DS. Seventy-five 
percent of them were introduced to DS by family or friends and 25% by a physician. Mostly 
frequently reported reasons of use were for good health (52%) and to provide energy (36%).63 
Another by Neuhouser et al., surveyed 104 adults on DS to know the sources of health 
information about each DS they are using and their motivations of using it. Part of that study was 
an open-ended question about all their sources of health information during the past 5 years. In 
addition, for each DS participants were asked what source of information motivated them to start 
taking it. The most common source of information reported was physician or nurse (71%) 
followed by print media sources (50%), broadcast media (40%), and family and friends (27%). 
About half of multivitamins/multiminerals, vitamin E and vitamin C users decided to take the DS 
based on advice from family members and friends. The health reasons behind using DS were to 
feel better for multivitamins/multiminerals users, to prevent acute illnesses such as colds and flu 
for vitamin C users, and to prevent chronic diseases for vitamin E and calcium users.64 
Pillitteri et al. assessed the prevalence of DS use for weight loss and examined the 
perception of its safety and efficacy by consumers. Study participants were asked whether they 
believed weight loss supplements were approved for safety by a government agency such as the 
FDA. More than half of the 1,444 adults in the in this study who had ever made a serious weight 
loss attempt incorrectly reported that weight loss DS were approved for safety by some 
government agency. This was true for those who use weight loss DS and those who did not.52  
The accuracy of information regarding recommendations or advice for DS use is a very 
important factor to ensure safe and proper use of these products. Studies above show that the use 
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of DS is mostly not related to evidence-based product benefits. These studies also indicate the 
need for better and more reliable information sources for DS consumers. 
 
Spontaneous Averse Events Reporting Systems 
 
Deﬁnitions of adverse event (AE) vary, but in general an AE is an unintended, undesired, 
or harmful effect associated with the use of a drug, intervention, or DS.17 The link between the 
DS and the AE could be established through the analysis of large number of AE reports. 
Spontaneous adverse event reporting systems are an approach used to capture post-marketing 
adverse events associated with the use of a drug, intervention, or DS. In the United States, FDA 
has developed the MedWatch system, which is a passive system, to identify post-marketing 
safety problems of drugs, biological products, and DS. The Center for Food Safety and Applied 
Nutrition (CFSAN) take responsibility for monitoring DS related AE through its Adverse Event 
Reporting System (AERS). FDA relies primarily on this system to generate signals of safety 
concerns that are then further assessed and analyzed. If there is an actual public health problem 
with a DS product, an appropriate safety action is taken against it. The MedWatch system has 
several limitations that reduce its ability to generate signals of safety concerns such as the low 
reporting rate of DS related AEs. An FDA report estimated that the agency receives less than 1% 
of all AEs associated with DS.48 With such low reporting rate, FDA finds it difficult or even 
impossible to quickly and effectively identify the potential risk associated with the use of DS. A 
report from FDA in 2001 stated that AERS received only 2,547 DS related reports from 1994 to 
1999 while more that 100 million consumers reported using DS during that period with 12% 
(11.9 million) of them having experienced adverse events.48 The number of reports received by 
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FDA is low as compared with other systems such as poison control centers (PCCs). As shown in 
Figure 2.2 in 1999 those centers received 1,300 reports while FDA received only 460 reports of 
DS related AEs.44 Because reporting to AERS is voluntary for consumers and healthcare 
professionals, they tend to report to local PCCs more that FDA.44  
Another limitation is the poor quality of information in a large proportion of AERS 
reports. This reduces the usefulness of such information in research and drawing conclusions.48 
In 1999, the MedWatch system received only 400 reports of DS related AEs, of which medical 
records were not available in 38% of cases, ingredients could not be determined in 32%, and 
there was no patient follow-up available in 27%.48 The usefulness of the MedWatch system for 
the detection of safety signals is questionable, and there have been calls for the creation of a 
better instrument.65 
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Figure 2.2 – Dietary Supplement adverse event reports received by FDA and PCCs from 
1997 to 1999 (reference 44) 
FDA: food and drug administration; PCCs: poison control centers 
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The Toxic Exposure Surveillance System (TESS) maintained by the American 
Association of Poison Control Centers (AAPCC) is another surveillance system that can be used 
to identify toxic exposure of any material including pharmaceuticals and DS. This system 
receives toxic exposure reports from all 60 PCCs in the U.S. and links it to the National Poison 
Data System (NPDS) database every 24 hours.66  
PCCs have an essential role in the post-marketing surveillance of the safety of 
pharmaceuticals, herbs and DS is essential.67-69 TESS database represents one potentially 
important source of information on consumer experiences with pharmaceuticals, herbs and DS. 
Starting from 2001, AAPCC began collecting data on botanicals reparably from DS. TESS data 
has been used in several studies on DS related AE.67-69 
Of 2,784,907 substances involved in the 2,384,825 human poison exposure reports from 
the 60 participating United States PCCs filed in TESS in 2010, 71,545 (2.6%) exposures 
involved vitamins, 32,052 (1.2%) involved dietary supplements, herbs, botanical products, and 
homeopathic preparations and 10,720 (0.38%) were exposures to essential oils 66 
Like MedWatch, TESS is also a passive reporting system, such that reporting of any toxic 
exposures to the system is voluntary for public and healthcare professionals. For this reason, 
TESS likely undercounts the true number of toxic exposures to a product in the public. In 
addition, the accuracy of data entry may vary. Missing or inaccurate information is another 
limitation of this system. Because the information is transcribed from the telephone calls by 
individuals, who are often anonymous, TESS reports sometimes lack important data elements. In 
addition, not all calls represent toxic exposures, and sometimes the toxic effects are not 
confirmed to be necessarily caused by the exposure.66 Sometimes, sensitive medical information 
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is not provided during the telephone calls from public or healthcare professionals, such that the 
accuracy and completeness of reporting may vary both by poison center and by case. The 
validity and usefulness of herbs and DS information in NPDS database is not confirmed and 
further research is needed in this area.65 
 
Reporting of Dietary Supplements Adverse Events 
 
Reports of DS related AEs are submitted to the FDA mainly by DS manufacturers, 
healthcare professionals, DS consumers, and PCCs. In a report commissioned by FDA, 20% of 
DS related AEs submitted to FDA came from healthcare professionals, and many were 
incomplete.48 In order for healthcare professionals to report a DS related AE, the patient must 
reveal that he is using a DS and experiencing an AE; however, patients do not always report use 
of DS to their healthcare professionals as mentioned before.51 Also, healthcare professionals 
believe they lack adequate information on how to detect and report DS related AE and 
recommend the need for additional training about DS.70, 71 
According to the FDA, about 50% of the reports were submitted to the FDA by 
consumers. When consumers report an AE they usually do not inform or involve their healthcare 
providers. This results in missing relevant medical information in many reports submitted by 
consumers. FDA may find it difficult or impossible to determine causality. For instance, the 
FDA reviewer may find it difficult to draw causality from case reports that were filled by 
consumers for the adverse event of kava and ephedra because of missing details of the DS 
product and patient characteristics.72-74 Consumers may lack information about DS regulation 
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and MedWatch system because of the limited role of FDA in communicating to the public 
regarding MedWatch system.48 
PCCs reporting system (TESS) receives substantially higher numbers of DS related AE 
reports compared to FDA’s MedWatch system.66, 67, 75, 76 This may be because PCCs are located 
in hospitals and because of their higher visibility to the public and local healthcare professionals. 
In 1999, the TESS system received 1,300 DS related AE reports while FDA received only 460 
reports (Figure 2.2). Only 1% of the reports received by TESS were reported to the MedWatch 
system.44 
As mentioned earlier, reporting of any DS related AE was voluntary without regulation 
until the DSNDCPA became effective in December 2007. This act requires the manufacturing 
party to submit a report of all serious AEs to the FDA MedWatch system within 15 days of their 
being notified of the AE. Moderate or mild AEs are not required to be reported to the FDA.12, 32 
The 2001 FDA report noted that FDA was unable to determine the manufacturer of DS products 
for 32% of the products involved in reports.48 
After DSNDCPA, number of DS related AE submitted to the MedWatch system saw a 
threefold increase compared with the previous year. In 2008, the MedWatch system received 
1080 DS related AE compared to 350 in 2007 and 317 in 2006.15, 48 Of the 1080 reports received 
in 2008, 662 were mandatory reports of serious AEs submitted by DS manufacturing party; the 
remaining 418 were voluntary reports including all mild, moderate and serious DS related AEs 
reported by consumers and healthcare practitioners to FDA.15 As shown in Figure 2.3, FDA 
received more serious AE reports related to DS than previous years including 2003 and 2004 
when several ephedra related AEs reports were submitted to FDA.48  The implementation of the 
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DSNDCPA dramatically increased the number of DS related AE reports from DS manufacturers. 
As shown in Figure 2.4, the number of mandatory reports of DS related AE reports increased 
every month from January through December 2008 and these numbers were always more than 
voluntary reports.15 
 
 
 
 
 
Figure 2.3 – The Number of DS-related adverse event reports to FDA MedWatch system 
from January 1, 2003, to October 31, 2008 (reference 48) 
FDA: food and drug administration 
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Figure 2.4 – The Number of DS-related adverse event reports to FDA MedWatch system 
from 2008 (reference 48) 
FDA: food and drug administration 
 
 
 
 
Reasons of Low Reporting Rate 
 
Comparing the number of adverse event reports received and entered into AERS database 
related to DS and drugs and biologics from 2003, through 2007, clearly indicate the low 
reporting rate of DS related AEs, as shown in Table 2.4. There are several possible reasons 
described in the literature for such low reporting rate. Certain characteristics of DS may 
contribute to the low reporting rate of its AEs.48 DS are “natural” products that are presumed to 
be safe by consumers, which may limit their willingness to link an AE with a “natural” product.7, 
17, 18 Also, DS are self-care products that consumers might choose to use without guidance or 
even knowledge of their healthcare professionals. Therefore, DS related AEs might be 
underreported.44 Another possible reason low reporting rate DS related AE to FDA is that 
consumers might have perceived lack of FDA involvement after reading the FDA disclaimer on 
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DS products that says, “This statement has not been evaluated by the Food and Drug 
Administration. This product is not intended to diagnose, treat, cure or prevent any disease.” 
Some consumers might think that FDA is not the right place to contact for any AE related to this 
product. 
 
 
Table 2.4 – Comparison of the number of adverse event reports received and entered into 
FDA’s databases for review related to ds and drugs and biologics, 2003, through 2007  
 
Description 
Year   
2003 2004 2005 2006 2007 Total Average 
Total dietary 
supplement reports 
recived and entred for 
review 
 
739 657 491 317 350 2,554 511 
Total drug and 
biologics reports 
recived and entred for 
review 
226,217 273,601 323,384 337,155 364,449 1,524,806 304,961 
Source: reference 48 
 
 
 
 
 
Summary  
 
In summary, reporting rate of serious and non-serious DS related AE to FDA is very low 
while their consumption is relatively high in the population. There are several potential AE that 
could be life threatening. The previous research to identify the reasons of such low reporting rate 
and how to overcome these factors is limited. In addition, factors considered in reporting a DA 
related AE could be different by profession. The research to understanding these factors is very 
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limited. Much is left to be done to better understand the effect of different variables on reporting 
rate of DS related AE and how to improve it. This study aims to investigate factors affecting 
practicing pharmacist’s decision to report DS related AE. 
 
 
35 
 
 
 
 
 
CHAPTER 3 METHODS 
 
 
 
 
Study Design 
 
A cross-sectional survey design was used in this project to collect information about 
selected attributes in making the decision to report a DS related AE. A new survey was 
developed for the purpose of this project based on previous studies with similar objectives.16, 28, 
29, 54, 77-80  
 
 
Study Population and Setting 
 
The study population was a convenience sample of pharmacists who were practicing and 
residing in the Commonwealth of Virginia as of October 2011. The sample was selected from a 
list of preceptors for PharmD students at the Virginia Commonwealth University School of 
Pharmacy. The list was composed of 764 practicing pharmacists at different locations in Virginia 
in a wide variety of practice settings. The list has information about each preceptor including the 
name, e-mail address, primary practice institution, and location. The use of a web-based 
questionnaire was determined to be beneficial over mailing paper questionnaires to facilitate 
participation from a range of practice settings that we have a handy access to it though the school 
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of pharmacy at Virginia Commonwealth University. There are several studies with reasonable 
response rate that used an online questionnaire in similar population.81-83 
All practicing pharmacists and pharmacy residents who served as preceptors for at least 
one PharmD student at the VCU School of Pharmacy were eligible for this study. Practicing 
pharmacists working in academia, industry, consulting companies as well as other settings were 
eligible. This allowed for comparison of pharmacists in a variety of settings in order to best meet 
objectives of this study. The approval of the VCU Institutional Review Board (IRB) was 
obtained before starting this project. 
 
 
Questionnaire Development 
 
The development of the questionnaire involved several steps as illustrated in Figure 3.1. 
The preliminary paper version of the questionnaire was developed based on previous relevant 
research and expert opinion. At That version was pilot tested and the final paper version was 
created based on pilot test feedback and comments. The version was tested for technical issues 
and the final web-based version was then created. This web-based version of the questionnaire 
was created using the Qualtrics online survey software.84  
 
A questionnaire composed of three sections was developed for the purpose of this project 
(Appendix B). The first section of the questionnaire presented four study scenarios consisting of 
different combinations of levels of the five attributes that were hypothesized to influence 
pharmacists’ decisions on reporting AE related to DS. These four study scenarios were randomly 
selected from a pool of 56 possible scenarios. As illustrated in Figure 3.3, this section of the 
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questionnaire was unique for each participant and all other sections of the questionnaire were the 
same for all participants. This section also had one holdout scenario that was fixed for all 
participants. The participants were asked to indicate their decision to report the AE in each 
scenario on a 6-point ordered scale, ranging from 1 (Definitely not report) to 6 (Definitely report) 
for each of the following four questions: 1. How likely are you to report the above adverse event 
to the prescriber?; 2. How likely are you to report the above adverse event to the drug 
manufacturer?; 3. How likely are you to report the above adverse event to the dietary supplement 
manufacturer?; and 4. How likely are you to report the above adverse event to FDA MedWatch 
system?  
In the second section of the questionnaire, set of questions were asked to measure  
responding pharmacists’ attitudes regarding the clinical use and safety of DS, encountering a 
patient with possible DS related AE, places to report DS related AE, their reporting patterns of 
AEs to different agencies, as well as their knowledge about DS and DS regulations. In addition, a 
set of questions about DS information recourse availability, usage, and usefulness were asked. 
The third section of the questionnaire contained a set of questions addressing 
demographics including age, gender, race and other characteristics of responding pharmacists 
including degree(s) earned, formal training related to DS or CAM, residency or fellowship, and 
current practice setting.  
In this study, the FDA definition of DS was used, which is “an ingredient that is included 
in the DS definition in DSHEA, such as vitamins, minerals, and herbs or other botanicals that is 
intended for human consumption.”7 This definition was provided in the participant information 
sheet at the beginning of the questionnaire (Appendix A). DS manufacturer and drug 
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manufacturer is the “responsible person.” By law, they are required to document their contact 
information including the domestic address or phone number on the label of their products. That 
could be the manufacturer, packer, or distributor.12, 85, 86 The drug manufacturer was used as one 
of the reporting places of the AE because patients in the scenarios were using concomitant drug 
therapy. Although the scenario described the patient as presenting with an AE that they were 
concerned was related to the DS, it is possible that participants attributed the AE to the drug 
therapy and not to the DS. Also, it is unclear whether pharmacists consider the DS manufacturer 
as an appropriate place for reporting AEs. 
 
 
 
39 
 
 
 
 
Figure 3.1 – Process of questionnaire development 
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Conjoint Analysis Exercise 
 
Conjoint analysis (CA) was first introduced as a survey measurement method in 
1964 in the field of mathematical psychology.87 It was then adopted and used in marketing 
research and economics. It was used in these areas for multi-attribute modeling of 
consumer preferences and choice at the individual and aggregate level. Five stages are 
involved in conducting conjoint analysis: identifying the attributes, assignment of levels to 
each attributes, developing presentation scenarios, obtaining preferences and data analysis. 
This technique combines both experimental designs and survey designs in which scenarios 
are used to determine attributes influencing respondents’ preferences or decisions in 
performing particular actions. The CA approach is generally similar to other methods that 
have been developed and used for understanding individuals’ preferences among 
alternatives such as discrete choice experimentation (DCE), stated preference discrete 
choice modeling and vignette analysis. 
In the last two decades, the technique of conjoint analysis has gained wide spread 
use in healthcare research to obtain the preferences of patients or individuals and 
communities in the delivery of healthcare services, determining optimal therapy options, 
managerial health decision making and as well as other applications.88, 89 Its application to 
preference assessment in health care decision making is relatively new but there has been a 
substantial increase in publications reporting its use to evaluate health related preferences 
in the last decade, as shown in Figure 3.1.90 
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Figure 3.2 – Numbers of published articles, by thematic structure and year of 
publication, on conjoint analysis in the clinical literature. (reference 90) 
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In a recent study, this technique was used to identify important attributes of the 
decision to purchase inﬂuenza vaccine in the U.S. by asking a nationally representative 
sample of 251 medical office managers and physicians about their preferences for seven 
vaccine related attributes.81 Another study used CA to evaluate how customers in Georgia 
selected a pharmacy to fill their prescriptions. A convenience sample of 175 consumers 
was surveyed, at four different pharmacy settings, on 26 attributes about “general 
pharmacy site features (16 items), pharmacist characteristics (5 items), and pharmacy staff 
characteristics (5 items).”91 Kievit et al. used adaptive conjoint analysis (ACA), a 
computer-based choice-based conjoint analysis, to determine the influence of attributes 
related to rheumatoid arthritis activity on the decision of rheumatologists to provide 
specialized care to patients. The study was conducted on a convenience sample of 135 
rheumatologists attending the annual meeting of the American College of Rheumatology. 
A total of six attributes (age of patient, initiation of DS, clinical symptoms, joint damage, 
disease activity, and current treatment) with three levels for each were used in this study.92 
 
For the purpose of this study, highly relevant attributes and levels were selected 
based on literature review.71, 93, 94 At beginning, six attributes were selected. Which were 
gender of the patient, age of the patient, time since initiation of the DS, time since last 
change of drug therapy, evidence supporting a DS related AE, and the outcome of the AE. 
However, after group discussion with practicing pharmacists, the gender of the patient 
attribute was deleted and instead gender was held constant in the scenarios to reduce the 
complexity of the scenarios. Also, the levels of time since initiation of the DS and time 
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since last change of drug therapy attributes reduces from three (1 weeks ago, 6 month ago, 
more than 2 years ago) to two (2 weeks ago and about 9 months ago). That is to allow 
sufficient time for the outcome of the AE to happen and to make the levels mutually 
exclusive. Both durations of 6 months ago and more than 2 years ago were considered as 
long durations in the preliminary testing so they were reduced into one duration of 9 
months ago. As listed in Table 3.1, five final attributes were selected for the purpose of this 
study. The attributes and levels selected manifested 144 possible case scenarios (3 × 2 × 2 
× 3 × 4 = 144). Instead of asking participants to evaluate all possible scenarios, a fractional 
factorial sample of scenarios was generated using the design of experiments function in 
SAS.95, 96  
The minimum number of scenarios needed for estimation of the main effects of the 
five attributes and the interaction terms was 56 different scenarios. In addition, one holdout 
case scenario was created separately from study scenarios for the purpose of validation and 
reliability of the responses. The holdout case scenario was judged by all respondents but its 
responses were not included in the analysis to estimate the importance of each attribute. 
All these scenarios were created and entered into the Qualtrics survey website. Using the 
question randomization function of Qualtrics, four randomly selected scenarios were 
chosen for each participant from the pool of all 56 study scenarios (Figure 3.3).  
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Table 3.1 – Attributes and levels included in the conjoint analysis study 
 
Attributes Levels 
1. Age of the patient a. 25 years 
b. 45 years 
c. 70 years 
2. Time since initiation of dietary 
supplement 
a. Within the past 2 weeks 
b. About 6 months ago 
3. Time since last change of drug 
therapy 
a. Within the past 2 weeks 
b. About 6 months ago 
4. Evidence of dietary supplement 
adverse events 
a. Consistent evidence in the literature 
b. Inconsistent (or mixed) evidence 
c. No evidence in the literature 
5. Outcome of the adverse event a. Self-limiting and resolved upon 
discontinuation of dietary supplement 
b. Required outpatient/ER† visit  
c. Required hospitalization 
d. Resulted in permanent disability 
ER: emergency room. 
  
 
 
45 
 
 
 
Figure 3.3 – Conceptual questionnaire design  
  
 
Section I: 
• 4 randomly selected study scenarios from a pool of 56 scenarios 
• 1 holdout scenario 
Section II: 
• Attitude, knowledge and information sources 
• 24 questions 
Section III: 
• Demographics, reporting, and practice setting 
• 8 questions 
Participant Information Sheet Title, purpose, significance, procedure, confidentiality, and definitions 
Unique for each 
Fixed for all  
Fixed for all  
Fixed for all  
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Questionnaire Pretesting 
 
The questionnaire was discussed and edited by the advisory committee. To assess 
feasibility and acceptability, a pilot test of the questionnaire was conducted with a group of 
pharmacy practice residents and fourth-year pharmacy students. In the pilot, test the 
following factors were considered: willingness of respondents to complete the 
questionnaire, the time required to complete the questionnaire, reasonable number of 
scenarios per questionnaire and the clarity of wording used in the questionnaire. The 
questionnaire was then revised based on feedback from the pilot test after discussion with 
the advisory committee. 
 
 
Questionnaire Distribution 
 
The Tailored Design Method involving multiple contacts with respondents to 
increase the response rate was used in this project.82 A notification e-mail with a brief 
description of the study was sent to all eligible pharmacists to introduce the study. The e-
mail contained a link to the web-based questionnaire (Appendix C). An information page 
presenting the purpose, procedure, significance, benefits and objective of the study was 
provided at the beginning of the questionnaire. Three “Thank You/Reminder” e-mails were 
sent to non-respondents two weeks, four weeks and five weeks after the notification e-mail 
(Appendix D).  All “Thank You/Reminder” messages had a link to the web-based 
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questionnaire. An end of survey “Thank You” message was shown to all respondents. No 
incentives were offered for completing the survey. 
 
 
Statistical Analysis 
 
Objective 1 – Determine the importance of selected attributes that influence a 
pharmacist’s decision to report an adverse event associated with the use of DS. 
 
The responses from the 56 scenarios were used to estimate part-worth utilities of 
each level and the importance of each attribute. All of these variables were numeric 
variables measured on a 6-point ordered scale, ranging from 1 (Definitely not report) to 6 
(Definitely report). There are four major dependent variables in this study representing the 
decisions of pharmacists to report an adverse event associated with the use of DS to the 
prescriber, the drug manufacturer, the DS manufacturer and the FDA MedWatch system. 
Each of these dependent variables was analyzed separately.  
The independent variables included the levels of each attribute used in the 
particular scenario, as well as other variables of pharmacists’ knowledge of DS and 
demographic characteristics. All independent variables from the scenario attributes were 
treated as categorical variables. Effects coding was used to represent the attributes levels 
using SAS experiment design tool. This is the recommended way of coding attributes in 
CA to allow estimations of both the main effects and interaction.97 All possible interactions 
between the attributes were considered in the design phase.  
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To measure the adjusted associations of each of the four dependent variables and 
associated attributes, a separate linear regression model containing only the attributes as 
independent variables was built for each dependent variable. A random effects option was 
used in the regression models to account for the lack of independence of the responses as 
each participating pharmacist responded to four study scenarios. The results of the 
regression models were used to generate a utility score (part-worth) for each attribute level 
and importance values, which are measures of how important each attribute was to the 
overall preference. These importance values were calculated by dividing the range of the 
utility scores for each attribute separately by the overall utility scores ranges for all 
attributes. The values thus represent percentages and have the property of summing to 100. 
As a check of validity of the utilities values, the differences between the observed 
and predicted preferences for the holdout scenarios was also measured and compared to the 
study scenarios. 
 
Objective 2 – Describe practicing pharmacists’ attitudes toward DS, 
knowledge about DS and understanding of their regulations, practice setting. 
 
Objective 3 – Describe the availability, usage and usefulness of common DS 
information resources. 
 
Descriptive statistics including the mean and standard deviation (SD) or median 
and 25th and 75th percentiles (interquartile range) for continuous variables or proportion 
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with 95% confidence intervals (CI) for categorical variables were calculated for attitudes, 
knowledge, demographic and other characteristics. Chi-squared tests for dichotomous 
variables, ANOVA for categorical variables with more than two levels, and two tailed 
Student’s t-tests for the continuous variables were used to test for differences. 
In order to score the two knowledge quizzes of DS and DS regulation, each correct 
answer was given a (1) and an incorrect answer or no answer was given a (0). Once all the 
answers were scored, each participant’s totals were added and divided by the total possible 
correct answers. The total score was stated as a percentage. 
 
Objective 4 – Determine the effect of pharmacist’s characteristics (objective 2) 
on the importance of the selected attributes that influence a pharmacist’s 
decision to report an adverse event associated with the use of DS (objective 1) 
 
To estimate the effect of pharmacists’ attitude, knowledge, demographics and other 
characteristics on their decisions to report, those variables were included as covariates in 
each of the four previously built models. Dummy variables were created for all categorical 
variables and they were included in each model to see if they changed the coefficients and 
part-worths for the profile attributes. 
In all data analyses, two-sided P values <0.05 were considered as statistically 
significant. SAS® version 9.2 software (SAS® Institute Inc., Cary, NC) and Stata® release 
12.1 for Windows (StataCorp LP, College Station, TX) were used to perform the statistical 
analysis. 
 
 
50 
 
 
Sample Size  
 
Sample size calculation within CA studies is a controversial issue.98 Previous CA 
studies that assessed decision preferences of healthcare professionals have used 150 
respondents or less.81, 89, 92 There are some “rules of thumb” which may be helpful in 
deciding the sample size for a conjoint analysis study.98 For example one formula used in 
traditional choice-based CA suggests that: 
 
 
In this study, the number of levels was five, total number of attributes was 14 and 
number of scenarios presented to each participant was five. Therefore, if this study were 
done using traditional full factorial choice-based CA, an adequate sample size for this 
study would be approximately 160 participants. However, this study used fractional 
factorial CA, which actually requires a smaller sample size.96  
 
  
(Number of Attributes Number of Levels + 1) 100 Sample Size =
Number of Tasks
− ×
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CHAPTER 4: RESULTS 
 
 
 
 
This project was conducted using a convenience sample of all pharmacists who 
serve as preceptors for PharmD students in the school of pharmacy at VCU. As of October 
2011, there were 764 preceptors at various institutions and locations. They were all 
contacted via email and asked to participate in the study. After the survey was e-mailed to 
the respondents, four reported no interest in participation and they were opted out from the 
reminder emails. E-mails to seven respondents were returned as “undeliverable” and one 
failed to be sent due to an incorrect e-mail address. This resulted in a total of 752 
preceptors invited to participate in this study. This may not have represented the study 
population who actually received the e-mails as some of the preceptors might not have 
been active or they might have changed their institutions. A total of 272 participants 
responded to the questionnaire. Of these, 66 questionnaires were partially completed and 
were excluded from the analysis. Thus, the final total number of questionnaires included in 
the analysis was 206. The estimated response rate based on 206 completed questionnaires 
from a potential 752 active preceptors was approximately 27%. 
Some of the variables were re-coded during the analysis. For instance, the “African 
American” category of the race/ethnicity variable was merged with the “Other” category 
because of low sample size. Also, the “health system inpatient pharmacy” and “health 
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system outpatient pharmacy” categories of the practice setting variable were merged 
together and all other categories except “community pharmacy” were merged with the 
“Other” category to allow comparison of the healthcare system and community practice 
settings. For some other comparisons, “health system outpatient pharmacy” and the 
“community pharmacy” categories of the practice setting variable were merged together to 
allow comparison of the inpatient healthcare system and community practice settings. 
 
 
Participants’ Demographic and Other Characteristics 
 
Respondent demographic information is reported in Table 4.1. Participants were 
predominantly female (129 [63.86%]). The race and ethnicity self-reported distribution 
was 167 (83.09%) Caucasian, 20 (9.95%) Asian/Asian American/Pacific Islander, 10 
(4.97%) African/African American, and 4 (1.99%) other. Participants’ ages ranged 
primarily from 30-59 years (136 [81%]). Only a few were younger than 30 or older than 60 
years. There were 134 (65.05%) participants who completed a Doctor of Pharmacy 
(PharmD) degree and 115 (55.82%) who completed a bachelor of science. Only a few had 
a graduate degree (27 [13.11%]). Approximately 32% finished a residency program after 
graduation; however, only few of them completed a fellowship after their residency (2%). 
About one fifth of the participants had formal training related to DS or CAM. The majority 
of the participants (95 [46.34%]) were working in a health system inpatient pharmacy or a 
community pharmacy (66 [32.20%]).  
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Table 4.1 – Participants’ demographic and other characteristic 
 
Characteristic (N) Categories 
Responses 
No. (%) 
Gender (202) Male 73 (36.14%) 
Female 129 (63.86%) 
Race/Ethnicity (201) Caucasian 167 (83.09%) 
African/African American 10 (4.97%) 
Asian/Asian American/Pacific Islander 20 (9.95%) 
Other 4 (1.99%) 
Age category  
(203) 
Younger than 30 years 25 (12.68%) 
30-39 years 56 (27.80%) 
40-49 years 55 (26.83%) 
50-59 years 52 (25.37%) 
60 years or older 15 (7.32%) 
Degree(s)* 
(206) 
Bachelor of Science (BS) 115 (55.82%) 
Doctor of Pharmacy (PharmD) 134 (65.05%) 
Graduate Degree 27 (13.11%) 
Residency or fellowship 
(205) 
Residency 65 (31.71%) 
Fellowship** 8 (3.90%) 
No 132 (64.39%) 
Formal training related to 
DS or CAM (204) 
Yes 42 (20.49%) 
No 162 (79.51%) 
Primary practice setting 
(205) 
Inpatient pharmacy 95 (46.34%) 
Community pharmacy† 66 (32.20%) 
Other†† 44 (21.46%) 
DS: dietary supplement; CAM: complementary and alternative medicine 
* Overlapping; denominator is not the same for each category as this is a select all that 
apply responses 
** 4 participants have completed both residency and fellowship 
† Health system outpatient pharmacy was included in this category 
†† This group includes home healthcare services, poison control center or drug information 
center, nursing home, skilled care or long- term care facility, ambulatory healthcare 
facility, academia 
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Reporting of Dietary Supplements Related Adverse Events 
 
Approximately 40 percent of participants had encountered a patient with a 
suspected AE related to DS during their practice (Table 4.2). Table 4.3 shows the 
description of reporting patterns of DS related AE to FDA MedWatch system, drug 
manufacturer and DS manufacturer.  Over half (110 [53.40%]) of the participants indicated 
that they had reported an AE to the FDA MedWatch system. However, only 8% included a 
DS in their reports to the MedWatch system. More participants had reported an AE to a 
drug manufacturer than to the MedWatch system. One hundred (48.54%) of the 
participants indicated that they had reported an AE to a drug manufacturer but never 
included a DS in their reports and 19 (9.22%) had included a DS in their reports. Unlike 
reporting to the MedWatch system and a drug manufacturer, reporting to a DS 
manufacturer was very limited. Only 11 (5.34%) had reported an adverse event to a DS 
manufacturer. 
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Table 4.2 – Encountered a suspected DS related adverse event 
 
Characteristic (N) Answers 
Responses 
No. (%) 
Encountered a patient with  
a suspected AE related to DS  
(206) 
Yes 83 (40.29%) 
No 123 (59.71%) 
DS: dietary supplement; AE: adverse event 
 
 
 
 
Table 4.3 – Reporting of DS related adverse event to FDA MedWatch, drug 
manufacturer and DS manufacturer 
 
Characteristic (N) Answers 
Responses 
No. (%) 
Reported an AE to the FDA  
MedWatch system 
(206) 
Yes, and I have included DS 16 (7.77%) 
Yes, but I never included DS 94 (45.63%) 
No 96 (46.60%) 
Reported an AE to a drug 
manufacturer 
(206) 
Yes, and I have included DS 19 (9.22%) 
Yes, but I never included DS 100 (48.54%) 
No 87 (42.23%) 
Reported an AE to a DS 
manufacturer 
(206) 
Yes, and I have included DS 11 (5.34%) 
No 195 (94.66%) 
FDA: Food and Drug Administration; DS: dietary supplement; AE: adverse event  
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Attitudes Toward Dietary Supplements 
 
Figure 4.1 and Table 4.4 show the description of the overall attitude the participants 
had toward the clinical use and the safety of DS. The overall attitude of the participants 
toward the clinical use of DS tended to be positive. A majority of the participants were 
positive or somewhat positive (67.50%). Table 4.4 shows the average attitude scores of 
participants toward the clinical use of DS considering the attitude score as a continuous 
variable ranging from 1 to 5 with 1 being the most positive score and 5 the most negative 
score. The average score of 2.90 (SD=1.09) was below the median of 3 (range=2-4) 
indicating a positive attitude.  
On the other hand, the overall attitude of the participants toward the safety of DS 
tended to be negative. Over 40% of the participants were negative or somewhat negative 
regarding safety. Table 4.4 shows the average attitude scores of participants toward the 
safety of DS considering the attitude score as a continuous variable ranging from 1 to 5 
with 1 being the most positive score and 5 the most negative score. The average score,  
3.20 (SD=0.99) was above the median of 3 (range=2-4) indicating a negative attitude. 
 
 
 
57 
 
 
 
Figure 4.1 – Overall attitudes of participants toward the clinical use of DS and the 
safety of DS. 
 
 
 
 
 
 
Table 4.4 – Average attitude scores of participants toward the clinical use of DS and 
the safety of DS 
 
Attitude toward No. of Responses Mean* (SD) Median (25%-75%) 
Clinical Use 206 2.90 (1.09) 3 (2 - 4) 
Safety 206 3.20 (0.99) 3 (2 - 4) 
DS: dietary supplement; SD: standard deviation 
* The mean of the five points scale responses when used as a continuous variable 
Clinical Use Safety
Positive 9.00% 3.80%
Somewhat positive 32.10% 22.60%
Neutral 26.40% 32.10%
Somewhat negative 25.90% 33.50%
Negative 6.60% 8.00%
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The average attitude scores toward the clinical use of DS showed no significant 
differences by gender, age categories, or race (Table 4.5). However, there is some 
variability in the average attitude score toward the clinical use of DS. Females tended to 
have a more positive attitude than males. Also, the average attitude toward the clinical use 
of DS becomes more positive as age category increases except for the 60 years or older 
category. In participants under age 30 the average attitude score was 3.16 (SD=1.02) 
compared to 2.71 (SD=1.14) for participants aged 50-59 years.  The mean was 3.13 
(SD=1.25) for the 60 years or older participants. Asian/Asian American/Pacific Islander 
participants had a negative attitude score 3.10 (SD=0.79) compared to Caucasians with a 
mean of 2.94 (SD=1.12) and other races who scored 2.46 (SD=0.97). The only significant 
difference in the attitude toward the clinical use of DS was between those who did and 
those who did not have formal training related to DS or CAM after graduation (p = 0.001). 
The average attitude score for those who did have formal training was 2.40 (SD=1.19) 
compared to 3.03 (SD=1.04) for those who did not have formal training. 
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Table 4.5 – Relationship between respondent characteristics and the attitude towards 
the clinical use of DS 
 
 
Categories 
Attitude toward the clinical use of DS 
Mean (SD) p-value 
Overall 
 
2.91 (1.09)  
Gender   0.309 
Male 3.00 (1.17)  
Female 2.84 (1.04)  
Age categories   0.370 
Younger than 30 
years 3.16 (1.02)  
30-39 years 3.00 (1.01)  
40-49 years 2.84 (1.10)  
50-59 years 2.71 (1.14)  
60 years or older 3.13 (1.25)  
Race/ 
Ethnicity*   
0.235 
Caucasian 2.94 (1.12)  
Asian/Asian 
American/ 
Pacific Islander 
3.10 (0.79)  
Other 2.46 (0.97)  
Formal training 
related to DS or 
CAM 
  0.001 
Yes 2.40 (1.19)  
No 3.03 (1.04)  
DS: dietary supplement; CAM: complementary and alternative medicine; SD: standard 
deviation 
* African American category was merged with “Other” category because of low sample 
size 
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The attitude toward the safety of DS showed no significant differences by gender, 
age categories, or races (Table 4.6). Participants of both gender categories and all age 
categories had negative average attitude scores related to the safety of DS. Both Caucasian 
and Asian/Asian American/Pacific Islander had a negative attitude compared to other 
races: 3.25 (SD=1.01), 3.35 (SD=0.81) and 2.77 (SD=0.83) respectively. The only 
significant difference in the average attitude toward safety of DS was between those who 
did and those who did not have formal training related to DS or CAM after graduation (p = 
0.009). The average attitude score for those who did have formal training was 2.86 
(SD=0.98) compared to 3.30 (SD=0.99) for those who did not have formal training. 
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Table 4.6 – Relationship between respondent characteristics and the average attitude 
responses toward the safety of DS 
 
 
Categories 
Attitude toward the safety of DS 
Mean (SD) p-value 
Overall 
 
3.21 (0.99)  
Gender   0.746 
Male 3.23 (1.02)  
Female 3.19 (0.97)  
Age categories   0.481 
Younger than 30 
years 3.40 (0.87)  
30-39 years 3.34 (1.01)  
40-49 years 3.18 (0.96)  
50-59 years 3.06 (1.09)  
60 years or older 3.07 (0.70)  
Race/ 
Ethnicity*   
0.204 
Caucasian 3.25 (1.01)  
Asian/Asian 
American/ 
Pacific Islander 
3.35 (0.81)  
Other 2.77 (0.83)  
Formal training 
related to DS or 
CAM 
  0.009 
Yes 2.86 (0.98)  
No 3.30 (0.99)  
DS: dietary supplement; CAM: complementary and alternative medicine; SD: standard 
deviation 
* African American category was merged with “Other” category because of low sample 
size 
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Knowledge of Dietary Supplements 
 
The average DS identification and DS regulation scores were used as continuous 
variables in all data analysis. The scores were also placed in categories of “0 to 20”, “21 to 
40”, “41 to 60”, “61 to 80” and “81 to 100” on the basis of the percentage of questions 
answered correctly for better representation and description. 
The results of both knowledge quizzes about DS identification and DS regulation 
are presented in Table 4.7, Figure 4.2, and 4.3. Participants’ knowledge about DS 
identification is better than their knowledge of DS regulation. The DS identification quiz 
was composed of 13 questions. Answers from 205 participants were considered in the 
analysis. One participant was dropped because of not answering any of the 9 questions. A 
total of 83 (40.30%) participants correctly answered all 9 DS identification questions. The 
mean (SD) score was 78.11 (24.21) as listed in Table 4.9. For better graphical 
representation of the DS identification and DS regulation scores, scores were placed in 
categories of “0 to 20”, “21 to 40”, “41 to 60”, “61 to 80” and “81 to 100” on the basis of 
the percentage of questions answered correctly. The histogram (Figure 4.2) shows the 
distribution of participants’ percentage scores on the DS identification quiz. The average 
scores were categorized into 5 categories of 20 points each for better description. As listed 
in figure 4.2, these categories are (0 to 20), (21 to 40), (41 to 60), (61 to 80), and (81 to 
100). Almost one half of the participants fall in the highest score category (81 to 100) and 
only 13.17% fall in the lowest score categories (0 to 20) and (21 to 40). About 20% of 
respondents fall in the middle score categories (41 to 60 or 61 to 80) 
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The DS regulation quiz was composed of 13 questions. For the analysis of this 
quiz, answers from 205 participants were considered. One participant was dropped because 
of not answering any of the 13 questions. Only one participant correctly answered all 13 
DS regulation questions. Three participants had a score of zero. The mean (SD) score was 
46.45 (16.91) as listed in Table 4.7. The histogram (Figure 4.3) shows the distribution of 
participants’ percentage scores on the DS regulation quiz. The average scores were 
categorized into five categories of 20 points each for better description. As listed in figure 
4.3, the same five categories used in the DS identification quiz are used in this quiz. 
Almost one half of the participants fall in the middle score category (41 to 60) and only 
one falls in the highest score category (81 to 100). About 20% of respondents fall in the 
middle score category (41 to 60) and about 24% in the lowest score categories (21 to 40) 
and (0 to 20). 
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Table 4.7 – Description of participants’ scores of the knowledge quizzes 
 
Knowledge of Mean (SD) Median (25%-75%) Range 
DS Identification  
n= 206 78.11 (24.21) 80 (60 - 100) 20 – 100 
DS Regulations  
n= 206 46.45 (16.91) 42.30 (42.30 – 53.84) 0 – 100 
DS: Dietary supplement; SD: Standard deviation 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – Distribution of participants’ average score of DS identification quiz 
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Figure 4.3 – Distribution of participants’ average score of DS regulation knowledge 
quiz 
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The knowledge scores of DS identification and regulation were compared with 
attitudes toward DS safely and clinical use, formal training on DS or CAM, and practice 
settings (Table 4.10). There were no significant differences in the average DS 
identification scores by attitude toward the safety and the clinical use of DS. Participants 
with a positive attitude toward the safety of DS, however, had higher scores and those with 
negative attitudes had lower scores: 87.74 (SD=24.08) and 73.09 (SD=24.82), respectively. 
Similarly, participants with positive attitudes toward the clinical use of DS had higher 
scores than those with negative attitudes: 83.56 (SD=21.52) and 73.95 (SD=24.96), 
respectively. The average DS identification score was higher for those who had formal 
training related to DS or CAM than those who did not have formal training related to DS 
or CAM, 80.71 (SD=24.13) and 77.47 (SD=25.40), respectively. The average score of 
participants from health system practice settings was significantly lower than those from 
community settings: 73.14 (SD=25.32) compared to 83.39 (SD=20.56), respectively (p = 
0.009). 
Unlike the average attitude score of DS identification, the average scores of DS 
regulation were slightly higher in those with negative or somewhat negative attitudes 
toward both safety and the clinical use of DS.  The average DS regulation knowledge score 
was higher for those who had formal training related to DS or CAM compared to those 
who did not have formal training treated to DS or CAM: 49.45 (SD=19.00) and 45.84 
(SD=16.34), respectively. The average score of participants from healthcare system 
practice settings was lower than those from community settings: 45.46 (SD=15.65) 
compared to 48.83 (SD=15.71), respectively. There were no significant differences in the 
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average DS regulation scores by attitude toward the safety and the clinical use of DS, 
regardless of formal training in DS or CAM or practice setting. 
 
 
 
68 
 
Table 4.8 – Distribution of average knowledge scores by attitude, formal training and 
practice setting 
 
 Attitude Categories 
DS 
identification 
Mean score (SD) p-value 
DS regulation 
Mean score (SD) p-value 
Overall  78.11 (24.21)  46.45 (16.91)  
Overall attitude 
toward the safety 
of DS 
  0.162  0.182 
Positive 95.71 (7.87)  48.90 (9.08)  
Somewhat 
positive 79.78 (24.08)  44.57 (15.76)  
Neutral 79.56 (23.65)  44.63 (17.72)  
Somewhat 
negative 75.59 (24.82)  47.96 (16.69)  
Negative 70.59 (26.33)  51.81 (19.66)  
Overall attitude 
toward the 
clinical use of DS 
  0.203  0.442 
Positive 85.00 (18.55)  47.01 (18.02)  
Somewhat 
positive 82.12 (21.52)  44.29 (14.54)  
Neutral 74.26 (26.61)  43.95 (19.17)  
Somewhat 
negative 76.48 (24.96)  50.93 (15.15)  
Negative 71.43 (27.97)  48.35 (21.37)  
Formal training 
related to DS or 
CAM 
  0.442  0.220 
Yes 80.71 (24.13)  49.45 (19.00)  
No 77.47 (25.40)  45.84 (16.34)  
Practice Setting   0.009  0.471 
Healthcare 
system 73.14 (25.32)  45.46 (15.65)  
Community† 83.39 (20.56)  48.83 (15.71)  
Other†† 83.64 (23.83)  45.89 (21.09)  
DS: dietary supplement; CAM: complementary and alternative medicine; SD: standard 
deviation 
† Health system outpatient pharmacy was included in this category to allow comparison 
between inpatient healthcare system and community practice settings 
†† This group includes home healthcare services, poison control center or drug information 
center, nursing home, skilled care or long- term care facility, ambulatory healthcare 
facility, academia  
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Formal Training Related to Dietary Supplement 
 
The results of subgroup analysis of the percentage distribution of those who did and 
did not have formal training related to DS or CAM are listed in table 4.11. Formal training 
is significantly different among practice setting (p = 0.002). The percentage of participants 
who had formal training is lower in healthcare system settings than in community settings: 
36.6% and 43.9%, respectively. Also, formal training is significantly higher among those 
who encountered a patient with a suspected adverse event related to DS than those who 
had not: 54.76% and 45.24% respectively (p = 0.027). Formal training might have 
increased the awareness of participants in detecting adverse events related to DS. The 
reporting pattern to the FDA MedWatch system, drug manufacturer and DS manufacturer 
differed based on the presence or absence of formal training. Those who had training were 
more likely to report (50.00%) and to include a DS in their report (14.29%) to FDA 
MedWatch system than those who had not had training: 44.17% and 6.13%, respectively 
(p = 0.002). Similarly, those who had training were significantly more likely to report 
(52.38%) and to include a DS in their report (21.43%) to drug manufacturer than those 
who had not had training: 6.13% and 46.63%, respectively (p = 0.002). Also, those who 
had training were significantly more likely to report a DS adverse event to DS 
manufacturer than those who had not had training: 14.29% and 3.07%, respectively (p = 
0.011).  
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Table 4.9 – Distribution of formal training related to DS or CAM by practice setting 
and reporting patterns 
 
Variable Categories 
Formal training related 
to DS or CAM 
p-value Yes (n=42) No (n= 163) 
Practice Setting     0.022 
Healthcare system 36.6%a 54.9%b  
Community 43.9%a 22.8%b  
Other 19.5%a 22.2%a  
Encountered a 
patient 
with a suspected 
AE 
related to DS 
    0.027 
Yes  54.76% 36.81%  
No 45.24% 63.19%  
Reported an AE to 
the FDA  
MedWatch system 
(206) 
   0.106 
Yes, and I have included DS 14.29% 6.13%  
Yes, but I never included DS 50.00% 44.17%  
No 35.71% 49.69%  
Reported an AE to  
a drug  
manufacturer 
(206) 
   0.002 
Yes, and I have included DS 21.43% 6.13%  
Yes, but I never included DS 52.38% 46.63%  
No 26.19% 47.24%  
Reported an AE to 
 a DS manufacturer 
(206) 
   0.011 
Yes 14.29% 3.07%  
No 85.71% 96.93%  
DS: dietary supplement; CAM: complementary and alternative medicine; AE: adverse 
event; FDA: food and drug administration  
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Dietary Supplement Information Resources 
 
Nine DS information resources were evaluated for their usage by participants, 
availability at practice site and usefulness as sources of information about DS. Usefulness 
was measured on a 5-point scale from 1 (not at all useful) to 5 (very useful).  Usage, 
availability and usefulness are presented in table 4.12. The list of references is sorted 
according to their usage by participants. The top four most commonly used resources were 
Lexi-Comp® (69.90%), Facts and Comparisons: Review of Natural Products (61.65%), 
Natural Medicines Comprehensive Database (by Pharmacist’s Letter) (57.77%), and 
Micromedex®: AltMedDex (47.57%). The Natural Therapeutics Pocket Guide was the 
least commonly used (7.28%). The top four most commonly available resources with Lexi-
Comp® on top of the list (65.38%) followed by Natural Medicines Comprehensive 
Database (by Pharmacist’s Letter) (62.41%), Facts and Comparisons: Review of Natural 
Products (56.87%), and Micromedex®: AltMedDex (50.67%). All of the resources were 
relatively useful with the minimum score of 3.03 and maximum score 4.21 out of 5. The 
most useful resource was Natural Medicines Comprehensive Database (by Pharmacist’s 
Letter) followed by The Complete German Commission E Monographs and Facts and 
Comparisons: Review of Natural Products; 4.21 (SD=0.8), 3.96 (SD=1.06), and 3.9 
(SD=0.95) respectively. The least useful resource was PDR for Herbal Medicines 3.03 
(SD=1.24). 
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Table 4.10 – Description of DS information resources experience, availability and 
usefulness 
 
DS Information resources 
Ever Used 
n (%) 
Availability 
n (%) 
Usefulness  
Mean (SD) 
Lexi-Comp® 
144 
(69.90%) 
102 
(65.38%) 
3.61 
(1.10) 
Facts and Comparisons: Review of Natural 
Products 
127 
(61.65%) 
91 
(56.87%) 
3.9 
(0.95) 
Natural Medicines Comprehensive 
Database (by Pharmacist’s Letter) 
119 
(57.77%) 
93 
(62.41%) 
4.21 
(0.8) 
Micromedex®: AltMedDex 
98 
(47.57%) 
75 
(50.67%) 
3.86 
(0.88) 
PDR for Herbal Medicines 
51 
(24.76%) 
30 
(21.27%) 
3.03  
(1.24) 
The Complete German Commission E 
Monographs 
41  
(19.90%) 
15 
(11.71%) 
3.96 
(1.06) 
Natural Standard Herb & Supplement 
Guide 
22 
(10.68%) 
17 
(14.65%) 
3.63 
(1.45) 
The Natural Therapeutics Pocket Guide 
15 
(7.28%) 
7 
(6.25%) 
3.44 
(1.15) 
Other* ----- 
13 
(6.31%) 
3.5 
(1.53) 
DS: dietary supplement: SD: standard deviation 
*Other resources include: NIH website National Center for Complementary and 
Alternative Medicine, Memorial Sloan Kettering Electronic Database, Epocrates website, 
First DataBank, Clinical Pharmacology, package insert of supplement, Martindale’s, 
Clinical Pharmacology Online. 
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Places to Report a Dietary Supplement Related Adverse Event 
 
The percentage distribution of participants’ self-reported opinion on places to 
report DS AE is described in Figure 4.4. The total number of responses is more than the 
total participants as they are responses to check all that apply. More than 90% of 
participants responded that they would report a DS AE to the prescribing healthcare 
provider. Reporting to FDA MedWatch system was the second highest followed by 
reporting to a DS manufacturer and to an internal safety review office; 86.34%, 53.17%, 
and 42.44% respectively. The analysis of percentage distribution of places to report a DS 
AE by practice setting is reported in table 4.13. Reporting to the prescribing healthcare 
provider and to DS manufacturer was not significantly different by practice setting. 
However, reporting to an internal safety review office (p < 0.001) and to the FDA 
MedWatch system was significantly different by practice setting (p =0.008).  The 
percentage of participants indicating an internal review office as a place to report a DS AE 
was significantly higher in healthcare system settings than in community or other practice 
settings; 70.10%, 12.60%, and 17.20% respectively. Similarly, the percentage of 
participants indicating the FDA MedWatch system office as a place to report a DS AE was 
significantly higher in healthcare system setting than in community or other practice 
setting; 52.50%, 23.70%, and 23.70% respectively. 
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Figure 4.4 – Percentage distribution of participant opinion on places to report a DS-
AE  
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Table 4.11 – Places to report a DS adverse event by practice setting 
 
Places to report 
Practice Setting (%)  
Healthcare system Community Other p-value 
The prescribing healthcare 
provider 
(n=187) 
51.30% 26.70% 21.90% 0.787 
Internal safety review 
office 
(n= 87) 
70.10% 12.60% 17.20% < 0.001 
FDA (MedWatch) 
(n=177) 52.50% 23.70% 23.70% 0.008 
DS Manufacturer 
(n=109) 48.00% 27.00% 25.00% 0.417 
DS: dietary supplement; FDA: food and drug administration 
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Conjoint Analysis 
 
Two models were run for each reporting place. Model-1 examined only the proﬁle 
attributes (patient’s age, initiation of DS, time since last change of drug therapy, evidence 
supporting the AE, and outcome of the AE). Model-2 examined the impact of other 
characteristics and all two-way interactions of the attributes on the pharmacist’s decision to 
report the AE. The average part-worth utility of each attribute level and the relative 
importance of each attribute were estimated for each reporting place: prescriber (model1-
1), drug manufacturer (model1-2), DS manufacturer (model1-3), and FDA (model1-4). 
Note that part-worths are the coefficients of random-effect linear regression models using 
the ordinary least square (OLS) method. They are relative measures and sum to zero for 
each attribute. In model-2, all two-way interaction terms between the five attributes were 
included, as explained earlier in the methods section. In addition, covariates from other 
characteristics were included as well. These interaction terms, covariates and other 
variables were retained only if they were significant at α-level of 0.05 in a separate 
backward stepwise selection regression model for each reporting place. The detailed results 
of these models are presented in Appendix F. 
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Reporting to the Prescriber (Model 1) 
 
Table 4.12 presents the average utility information of each attribute level that 
participants used to make their decision to report the AE to the prescriber. No interaction 
terms or covariate of other participant characteristics were included in this model. The 
average part-worth utility with the 95% CI, standard error, and the significance level of 
each attribute level are listed.  
There was no significant difference in the part-worth utility of each level of the age 
of patient attribute (level “25 years”, “45 years”, or “70 years”) and the mean utility of this 
attribute (zero). The mean utility of any attribute is zero because effect coding was used in 
this regression model and the sum of utilities must be zero. The utility range of this 
attribute was (0.10). For the Initiation of DS attribute, the part-worth utility for reporting to 
the prescriber if DS was initiated “within the past 2 weeks” is significantly higher than 
zero, 0.09 (95% CI= 0.00, 0.18) (p = 0.043) and less than zero if DS was initiated “about 6 
months ago”. The utility range of this attribute was (0.19). For the time since last change of 
drug therapy attribute, the part-worth utility for reporting to the prescriber if drug therapy 
was last changed “within the past 2 weeks” is not significantly higher than zero and less 
than zero if DS was changed “about 6 months ago”. The utility range of this attribute was 
(0.16). 
The part-worth utility for change of drug therapy “within the past 2 weeks” was not 
significantly different from 0. The evidence of the AE in the literature (utility range = 0.85) 
and the outcome of the AE had higher participants’ utility (utility range = 1.58) in making 
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the decision to report an AE than other attributes utilities, (Table 4.20). For the evidence of 
AE attribute, the average participants’ utility for reporting to the prescriber was 0.69 
(reference) if there was consistent evidence in the literature supporting the AE. On the 
other hand, if there was no evidence in the literature supporting the AE, the average 
participants’ utility for reporting the AE to the prescriber is significantly less than zero at -
0.78 (95% CI=-0.91, -0.65) (p<0.001), and it was not significantly different from zero if 
there was inconsistent (or mixed) evidence in the literature. 
The average participants’ utility for reporting to the prescriber was significantly 
more than zero, 0.54 (95% CI=0.37, 0.71) (p<0.001), if the AE resulted in permanent 
disability, significantly more than zero if the AE required hospitalization, 0.18 (95% 
CI=0.03, 0.34) (p = 0.023), and not significantly different from zero if it required 
outpatient or emergency room (ER) visit. On the other hand, if the outcome of the AE was 
self-limited, meaning that it resolved upon discontinuation of DS, the average participants’ 
utility for reporting to the prescriber was -0.76 (reference). 
As in figure 4.5 and Table 4.20, the most important attribute in reporting a DS 
related AE to the prescriber was the evidence supporting the AE (45.25%) followed by the 
outcome of the AE (39.58%). Initiation of DS, time since change of drug therapy and age 
of the patient were not as important. 
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Table 4.12 – Results of the conjoint analysis for reporting to the prescriber (model 1) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years -0.06 (Reference*) — — 
b. 45 years -0.08 (-0.21,  0.05) 0.07 0.214 
c. 70 years 0.02 (-.11, 0.15) 0.07 0.753 
2. Initiation of DS† a. Within the past 2 weeks 0.09 (0.00, 0.18) 0.05 0.043 
b. About 6 months ago -0.09 (Reference*) — — 
3. Time since last 
change of drug 
therapy 
a. Within the past 2 weeks 0.08 (-0.01, 0.17) 0.05 0.093 
b. About 6 months ago -0.08 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in the 
literature 0.69 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.09 (-0.04, 0.22) 0.07 0.173 
c. No evidence in the 
literature -0.78 (-0.91, -0.65) 0.07 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -0.74 (Reference*) — — 
b. Required outpatient/ER 
visit 0.02 (-0.14, 0.18) 0.08 0.786 
c. Required hospitalization 0.18 (0.03, 0.34) 0.08 0.023 
d. Resulted in permanent 
disability 0.54 (0.37, 0.71) 0.08 <0.001 
Constant   4.44 (4.28, 4.61) 0.08 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
811 
213 
30.28% 
285.33 
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
† The attribute is significantly different from zero at p = 0.05 level (Table 4.22) 
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Figure 4.5 – Relative importance of attributes for reporting to the prescriber (model 
1) 
DS: dietary supplement; AE: adverse event 
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Reporting to the Prescriber (Model 2) 
 
Table 4.15 presents the adjusted average part-worth utility of each attribute level 
that participants used to decide on reporting the AE to the prescriber. The significant 
interaction terms between attributes and the significant covariate of other participant’s 
characteristics were included in the model. None of the interaction terms were retained in 
the backward selection model. The covariates that were retained in the backward selection 
model and in the adjusted model 2 were “encountered a patient with a suspected DS-AE”, 
“primary practice setting in outpatient pharmacy”, “overall attitude toward the safety of 
DS”, “African American ethnicity”, “no previous reporting of an AE to the FDA 
MedWatch system”, “overall attitude toward the clinical use of DS”, “the status of not 
completing residency or fellowship program”, and “primary practice setting in ambulatory 
healthcare facility” (Appendix F). 
After including the significant interaction terms and covariates, the initiation of DS 
within the past 2 weeks was no longer significant, 0.09 (95% CI= 0.00, 0.19) (p = 0.053). 
No other significance levels changed. The size of some part-worth utilities and the 
importance of the some attributes, however, resulted in some small changes after including 
the significant interaction terms and covariates. The part-worth utility of change in drug 
therapy in the past 2 weeks decreased from 0.08 to 0.05. The importance of outcome of the 
AE increased from 39.58% to 41.21% and the importance of time since last change in drug 
therapy decreased from 4.99% to 2.74%. The small changes in importance of other are also 
reported (Figure 4.6). The range of part-worth utilities changed as well after including the 
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significant interaction terms and covariates (Table 4.20 and Table 4.21). The “time since 
last change of drug therapy” attribute produced the largest change; from 0.16 to 0.09. The 
“age of patient” attribute resulted in a small increase and the other attributes resulted in 
small decrease.  
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Table 4.13 – Results of the conjoint analysis for reporting to the prescriber (model 2) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years 0.07 (Reference*) — — 
b. 45 years -0.10 (-0.23, 0.03) 0.07 0.137 
c. 70 years 0.03 (-.11, 0.16) 0.07 0.699 
2. Initiation of DS a. Within the past 2 weeks 0.09 (0.00, 0.19) 0.05 0.053 
b. About 6 months ago -0.09 (Reference*) — — 
3. Time since last 
change of drug 
therapy 
a. Within the past 2 weeks 0.05 (-0.05, 0.14) 0.05 0.356 
b. About 6 months ago -0.05 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in the 
literature 0.69 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.12 (-0.01, 0.26) 0.07 0.079 
c. No evidence in the 
literature -0.82 (-0.95, -0.68) 0.07 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -0.79 (Reference*) — — 
b. Required outpatient/ER 
visit 0.03 (-0.13, 0.20) 0.08 0.701 
c. Required hospitalization 0.21 (0.05, 0.37) 0.08 0.011 
d. Resulted in permanent 
disability 0.57 (0.39, 0.74) 0.09 <0.001 
Constant   4.75 (4.06, 5.45) 0.35 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
754 
196 
32.89% 
322.51 
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
**No significant interaction terms were retained at p = 0.05 level 
† The attribute is significantly different from zero at p = 0.05 level (Table 4.23) 
Note: see appendix F for complete results with the covariates that were retained in this 
model 
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Figure 4.6 – Relative importance of attributes for reporting to the prescriber (model 
2) 
DS: dietary supplement; AE: adverse event 
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Reporting to the Drug Manufacturer (Model 1) 
 
Table 4.14 presents the average utility information of each attribute level that 
participants used to make their decision to report the AE to the drug manufacturer. No 
interaction terms or covariate of other participant characteristics were included in this 
model. The average part-worth utility with the 95% CI, standard error, and the significance 
level of each attribute level are listed.  
There was no significant difference in the part-worth utility of each level of the age 
of patient attribute (level “25 years”, “45 years”, or “70 years”) and the mean utility of this 
attribute (zero). The utility range of this attribute was (0.11). For the initiation of DS 
attribute, the part-worth utility for reporting to the drug manufacturer if DS was initiated 
“within the past 2 weeks” is significantly higher than zero, 0.14 (95% CI= 0.05, 0.22) (p = 
0.002) and non-significantly lower than zero if DS was initiated “about 6 months ago”. 
The utility range of this attribute was (0.27). For the time since last change of drug therapy 
attribute, the part-worth utility for reporting to the prescriber if drug therapy was last 
changed “within the past 2 weeks” is not significantly higher than zero and less than zero if 
DS was changed “about 6 months ago”. The utility range of this attribute was (0.17). 
Changing of drug therapy “within the past 2 weeks” had not significantly more 
part-worth utility and “about 6 months ago” had not significantly less part-worth utility 
than zero in reporting the AE to the drug manufacturer. 
The evidence of the AE in the literature (utility range = 0.85) and the outcome of 
the AE had higher participants’ utilities (utility range = 1.58) in making the decision to 
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report an AE than other attributes utilities, (Table 4.20). For the evidence of AE attribute, 
the average participants’ utility for reporting to the drug manufacturer is 0.38 (reference) if 
there was consistent evidence in the literature supporting the AE. On the other hand, if 
there was no evidence in the literature supporting the AE, the average participants’ utility 
for reporting the AE to the drug manufacturer was significantly less than zero at -0.47 
(95% CI=-0.60, -0.35) (p<0.001) and it was not significantly different from zero if there 
was inconsistent (or mixed) evidence in the literature. 
The average participants’ utility for reporting to the drug manufacturer was 
significantly more than zero, 0.82 (95% CI=0.67, 0.98) (p<0.001), if the AE resulted in 
permanent disability, not significantly different from zero if the AE required 
hospitalization, and significantly less than zero, -0.15 (95% CI=-0.30, 0.00) (p = 0.046), if 
it required outpatient or ER visit. On the other hand, if the outcome of the AE was self-
limited and resolved upon discontinuation of DS, the average participants’ utility for 
reporting to the drug manufacturer was -0.76 (reference). 
As in Figure 4.7, the most important attribute in reporting a DS related AE to the 
drug manufacturer were the outcome of the AE (53.55%) followed by the evidence 
supporting the AE (28.85%) and initiation of DS (9.15%). Time since change of drug 
therapy and age of the patient were not as important. 
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Table 4.14 – Results of the conjoint analysis for reporting to the drug manufacturer 
(model 1) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years 0.01 (Reference*) — — 
b. 45 years -0.06 (-0.18, 0.06) 0.06 0.319 
c. 70 years 0.05 (-.07, 0.17) 0.06 0.445 
2. Initiation of DS† a. Within the past 2 weeks 0.14 (0.05, 0.22) 0.04 0.002 
b. About 6 months ago -0.14 (Reference*) — — 
3. Time since last 
change of drug 
therapy 
a. Within the past 2 weeks 0.09 (-0.01, 0.17) 0.05 0.057 
b. About 6 months ago -0.09 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in 
the literature 0.38 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.09 (-0.03, 0.22) 0.06 0.147 
c. No evidence in the 
literature -0.47 (-0.60, -0.35) 0.06 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -0.76 (Reference*) — — 
b. Required outpatient/ER 
visit -0.15 (-0.30, 0.00) 0.08 0.046 
c. Required hospitalization 0.09 (-0.06, 0.24) 0.08 0.238 
d. Resulted in permanent 
disability 0.82 (0.67, 0.98) 0.08 <0.001 
Constant   3.06 (2.88, 3.25) 0.09 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
811 
213 
26.67% 
239.69 
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
† The attribute is significantly different from zero at p = 0.05 level (Table 4.22) 
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Figure 4.7 – Relative importance of attributes for reporting to the drug manufacturer 
(model 1) 
DS: dietary supplement; AE: adverse event 
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Reporting to the Drug Manufacturer (Model 2) 
 
Table 4.15 presents the adjusted average part-worth utility of each attribute level 
that participants used to decide on reporting the AE to the drug manufacturer. The 
significant interaction terms between attributes and the significant covariate of other 
participant’s characteristics were included in the model. None of the interaction terms were 
retained in a backward selection model of all attributes, interactions and covariates. The 
covariates that were retained in the backward selection model and were included in the 
adjusted model 2 are “primary practice setting in community pharmacy”, “overall attitude 
toward the clinical use of DS”, “did not encounter a patient with a suspected DS-AE”, 
“previous reporting of an AE to the FDA MedWatch system without including a DS in the 
report”, “overall attitude toward the safety of DS”, “primary practice setting in ambulatory 
academia”, “other races”, “primary practice setting in ambulatory healthcare facility”, 
“African American ethnicity”, “no previous reporting of an AE to the drug manufacturer”, 
and “previous reporting of an AE to the DS manufacturer” (Appendix F). 
After including the significant interaction terms and covariates, the significance 
levels of the attributes did not change. The size of some part-worth utilities and the 
importance of the some attributes, however, resulted in some small change after including 
the significant interaction terms and covariates (Table 14 and Table 15). The importance of 
other attributes produced small changes. The largest change was in the “age of patient”; 
increasing from 2.56% to 4.04% (Figure 4.6). The range of part-worth utilities changed as 
well after including the significant interaction terms and covariates (Table 4.20 and Table 
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4.21). The “time since last change of drug therapy” attribute resulted in a small decrease 
and the other attributes resulted in a small increase. 
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Table 4.15 – Results of the conjoint analysis for reporting to the drug manufacturer 
(model 2) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years 0.03 (Reference*) — — 
b. 45 years -0.08 (-0.20, 0.05) 0.06 0.223 
c. 70 years 0.05 (-.08, 0.18) 0.07 0.474 
2. Initiation of DS† a. Within the past 2 weeks 0.15 (0.06, 0.24) 0.05 0.001 
b. About 6 months ago -0.15 (Reference*) — — 
3. Time since last 
change of drug 
therapy 
a. Within the past 2 weeks 0.08 (-0.02, 0.17) 0.05 0.106 
b. About 6 months ago -0.08 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in 
the literature 0.40 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.11 (-0.02, 0.25) 0.07 0.085 
c. No evidence in the 
literature -0.51 (-0.64, -0.39) 0.06 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -0.77 (Reference*) — — 
b. Required outpatient/ER 
visit -0.17 (-0.33, -0.02) 0.08 0.029 
c. Required hospitalization 0.10 (-0.06, 0.25) 0.08 0.218 
d. Resulted in permanent 
disability 0.85 (0.68, 1.01) 0.08 <0.001 
Constant   5.49 (3.37, 7.26) 0.90 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
758 
197 
28.30% 
288.10 
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
† The attribute is significantly different from zero at p = 0.05 level (Table 4.23) 
Note: see appendix F for complete results with the interaction terms and the covariates that 
were retained in this model 
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Figure 4.8 – Relative importance of attributes for reporting to the drug manufacturer 
(model 2) 
DS: dietary supplement; AE: adverse event 
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Reporting to the Dietary Supplement Manufacturer (Model 1) 
 
Table 4.16 presents the average utility information of each attribute level that 
participants used to make their decision to report the AE to the DS manufacturer. No 
interaction terms or covariate of other participant’s characteristics were included in this 
model. The average part-worth utility with the 95% CI, standard error, and the significance 
level of each attribute level are listed.  
There was no significant difference in the part-worth utility of each level of the age 
of patient attribute (level “25 years”, “45 years”, or “70 years”) and the mean utility of this 
attribute (zero). The utility range of this attribute was (0.17). Initiation of DS “within the 
past 2 weeks” had not significantly more part-worth utility and “about 6 months ago” had 
not significantly less part-worth utility than zero in reporting the AE to the DS 
manufacturer. The utility range of this attribute was (0.09). For the time since last change 
of drug therapy attribute, the part-worth utility for reporting to the prescriber if drug 
therapy was last changed “within the past 2 weeks” is not significantly higher than zero 
and less than zero if DS was changed “about 6 months ago”. The utility range of this 
attribute was (0.20). 
For the changing of drug therapy attribute, the part-worth utility for reporting to the 
DS manufacturer was significantly higher than zero, 0.10 (95% CI= 0.01, 0.18) (p = 0.026) 
if drug therapy was changed “within the past 2 weeks” and was not significantly less than 
zero if drug therapy was initiated “about 6 months ago”. 
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The evidence of the AE in the literature (utility range = 0.81) and the outcome of 
the AE resulted in higher participants’ utilities (utility range = 1.43) in making the decision 
to report an AE than other attributes utilities, (Table 4.20). For the evidence of AE 
attribute, the average participants’ utility for reporting the AE to the DS manufacturer was 
0.41 (reference) if there was consistent evidence in the literature supporting the AE. On the 
other hand, if there was no evidence in the literature supporting the AE, the average 
participants’ utility for reporting the AE to the DS manufacturer was significantly less than 
zero at -0.41 (95% CI=-0.52, -0.29) (p<0.001) and it was not significantly different from 
zero if there was inconsistent (or mixed) evidence in the literature. 
The average participants’ utility for reporting to the DS manufacturer was 
significantly more than zero, 0.79 (95% CI=0.64, 0.95) (p<0.001), if the AE resulted in 
permanent disability, not significantly different from zero if the AE required 
hospitalization and significantly less than zero if it required outpatient or ER visit, -0.20 
(95% CI=-0.35, -0.06) (p = 0.006). On the other hand, if the outcome of the AE was self-
limited and resolved upon discontinuation of DS, the average participants’ utility for 
reporting to the DS manufacturer was -1.03   (reference). 
As in figure 4.9 and Table 4.20, the most important attribute in reporting a DS 
related AE to the DS manufacturer were the outcome of the AE (49.57%) followed by the 
evidence supporting the AE (33.91%). Initiation of DS, time since change of drug therapy 
and age of the patient were not as important. 
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Table 4.16 – Results of the conjoint analysis for reporting to the dietary supplement 
manufacturer (model 1) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years -0.02 (Reference*) — — 
b. 45 years -0.07 (-0.19,  0.04) 0.06 0.210 
c. 70 years 0.09 (-.03, 0.21) 0.06 0.130 
2. Initiation of DS a. Within the past 2 weeks 0.05 (-0.04, 0.13) 0.04 0.265 
b. About 6 months ago -0.05 (Reference*) — — 
3. Time since last 
change of drug 
therapy† 
a. Within the past 2 weeks 0.10 (0.01, 0.18) 0.04 0.026 
b. About 6 months ago -0.10 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in 
the literature 0.41 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.00 (-0.12, 0.12) 0.06 0.971 
c. No evidence in the 
literature -0.41 (-0.52, -0.29) 0.06 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -1.03 (Reference*) — — 
b. Required outpatient/ER 
visit -0.20 (-0.35, -0.06) 0.07 0.006 
c. Required hospitalization 0.04 (-0.10, 0.18) 0.07 0.557 
d. Resulted in permanent 
disability 0.79 (0.64, 0.95) 0.08 <0.001 
Constant   2.85 (2.67, 3.03) 0.09 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
811 
213 
24.61% 
215.78 
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
† The attribute is significantly different from zero at p = 0.05 level (Table 4.22) 
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Figure 4.9 – Relative importance of attributes for reporting to the dietary supplement 
manufacturer (model 1) 
DS: dietary supplement; AE: adverse event 
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Reporting to the Dietary Supplement Manufacturer (Model 2) 
 
Table 4.17 presents the adjusted average part-worth utility of each attribute level 
that participants used to decide on reporting the AE to the DS manufacturer. The 
significant interaction terms between attributes and the significant covariate of other 
participant characteristics were included in the model. None of the interaction terms were 
retained in a backward selection model of all attributes, interactions and covariates. The 
covariates that were retained in the backward selection model and were included in the 
adjusted model-2 were “no previous reporting of an AE to the drug manufacturer”, 
“primary practice setting in ambulatory healthcare facility”, “no previous reporting of an 
AE to the DS manufacturer”, “African American ethnicity”, “female gender”, “the status 
of not completing either residency or fellowship program”, “did not encounter a patient 
with a suspected DS-AE”,  and “no previous reporting of an AE to the drug manufacturer”; 
(Appendix F). 
After including the significant interaction terms and covariates, the significance 
levels of the attributes did not change. The size of some part-worth utilities and the 
importance of the some attributes, however, resulted in some small changes after including 
the significant interaction terms and covariates (Table 16 and Table 17). The importance of 
other attributes also resulted in some changes. The “evidence of AE” decreased from 
33.91% to 29.85%, the “initiation of DS” decreased form 6.81% to 3.92%, and the “age of 
patient” increased from 2.85% to 6.79% (Figure 4.9 and Figure 4.10). The range of part-
worth utilities changed as well after including the significant interaction terms and 
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covariates (Table 4.20 and Table 4.21). The “time since last change of drug therapy” 
attribute resulted in a small decrease and the other attributes resulted in small increases. 
The largest changes were in “age of patient” that increased from 0.17 to 0.19 and 
“initiation of DS” that increased from 0.09 to 0.11. 
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Table 4.17 – Results of the conjoint analysis for reporting to the dietary supplement 
manufacturer (model 2) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years -0.01 (Reference*) — — 
b. 45 years -0.09 (-0.22, 0.03) 0.06 0.132 
c. 70 years 0.10 (-0.03, 0.22) 0.06 0.125 
2. Initiation of DS a. Within the past 2 weeks 0.06 (-0.03, 0.14) 0.04 0.212 
b. About 6 months ago -0.06 (Reference*) — — 
3. Time since last 
change of drug 
therapy† 
a. Within the past 2 weeks 0.10 (0.01, 0.19) 0.05 0.035 
b. About 6 months ago -0.10 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in the 
literature 0.41 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.02 (-0.10, 0.15) 0.06 0.730 
c. No evidence in the 
literature -0.43 (-0.56, -0.31) 0.06 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -1.09 (Reference*) — — 
b. Required outpatient/ER 
visit -0.21 (-0.36, -0.05) 0.08 0.008 
c. Required hospitalization 0.04 (-0.11, 0.19) 0.08 0.598 
d. Resulted in permanent 
disability 0.82 (0.66, 0.98) 0.08 <0.001 
Constant   4.99 (3.36, 6.61) 0.83 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
746 
194 
26.04% 
245.51 
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
**No significant interaction terms were retained at p = 0.05 level 
† The attribute is significantly different from zero at p = 0.05 level (Table 4.23) 
Note: see appendix F for complete results with the covariates that were retained in this 
model 
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Figure 4.10 – Relative importance of attributes for reporting to the dietary 
supplement manufacturer (model 2) 
DS: dietary supplement; AE: adverse event 
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Reporting to the FDA (Model 1) 
 
Table 4.18 presents the average utility information of each attribute level that 
participants used to make their decision to report the AE to FDA. No interaction terms or 
covariate of other participant characteristics were included in this model. The average part-
worth utility with the 95% CI, standard error, and the significance level of each attribute 
level are listed.  
There was no significant difference in the part-worth utility of each level of the age 
of patient attribute (level “25 years”, “45 years”, or “70 years”) and the mean utility of this 
attribute (zero). The utility range of this attribute was (0.10). Initiation of DS “within the 
past 2 weeks” had significantly more part-worth utility than zero, 0.11 (95% CI= 0.03, 
0.20) (p = 0.011) and “about 6 months ago” had less part-worth utility than zero in 
reporting the AE to FDA. The utility range of this attribute was (0.23). 
For the changing of drug therapy attribute, the part-worth utility for reporting to the 
FDA MedWatch system was significantly more than zero, 0.12 (95% CI= 0.02, 0.21) (p = 
0.013) if drug therapy was changed “within the past 2 weeks” and was less than zero if 
drug therapy was initiated “about 6 months ago”. The utility range of this attribute was 
(0.23). 
The evidence of the AE in the literature (utility range = 1.14) and the outcome of 
the AE resulted in higher participants’ utility (utility range = 1.67) in making the decision 
to report an AE than other attributes utilities, (Table 4.20). For the evidence of AE 
attribute, the average participants’ utility for reporting the AE to FDA was 0.54 (reference) 
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if there was consistent evidence in the literature supporting the AE. On the other hand, if 
there was no evidence in the literature supporting the AE, the average participants’ utility 
for reporting the AE to FDA was significantly less than zero -0.60 (95% CI=-0.72, -0.47) 
(p<0.001) and it was not significantly different from zero if there was inconsistent (or 
mixed) evidence in the literature. 
The average participants’ utility for reporting to the FDA MedWatch system was 
significantly more than zero, 0.84 (95% CI=0.67, 1.00) (p<0.001), if the AE resulted in 
permanent disability, significantly more than zero if the AE required hospitalization 0.19 
(95% CI=0.04, 0.34) (p = 0.015), and significantly less than zero if it required an 
outpatient or ER visit, -0.19 (95% CI=-0.34, -0.04) (p = 0.016). On the other hand, if the 
outcome of the AE was self-limited and resolved upon discontinuation of DS, the average 
participants’ utility for reporting to FDA was -0.83  (reference). 
As in figure 4.11 and Table 4.20, the most important attribute in reporting a DS 
related AE to FDA were the outcome of the AE (49.57%) followed by the evidence 
supporting the AE (33.91%). Initiation of DS, time since change of drug therapy and age 
of the patient were not as important.  
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Table 4.18 – Results of the conjoint analysis for reporting to the FDA (model 1) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years 0.02 (Reference*) — — 
b. 45 years -0.06 (-0.18, 0.06) 0.06 0.345 
c. 70 years 0.04 (-.09, 0.61) 0.06 0.572 
2. Initiation of DS† a. Within the past 2 weeks 0.11 (0.03, 0.20) 0.04 0.011 
b. About 6 months ago -0.11 (Reference*) — — 
3. Time since last 
change of drug 
therapy† 
a. Within the past 2 weeks 0.12 (0.02, 0.21) 0.05 0.013 
b. About 6 months ago -0.12 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in 
the literature 0.54 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.06 (-0.07, 0.18) 0.07 0.399 
c. No evidence in the 
literature -0.60 (-0.72, -0.47) 0.06 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -0.83 (Reference*) — — 
b. Required outpatient/ER 
visit -0.19 (-0.34, -0.04) 0.08 0.016 
c. Required hospitalization 0.19 (0.04, 0.34) 0.08 0.015 
d. Resulted in permanent 
disability 0.84 (0.67, 1.00) 0.08 <0.001 
Constant   3.31 (3.12, 3.50) 0.10 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
811 
213 
31.92% 
304.58  
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
† The attribute is significantly different from zero at p = 0.05 level (Table 4.22) 
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Figure 4.11 – Relative importance of attributes for reporting to the FDA MedWatch 
system (model 1) 
DS: dietary supplement; AE: adverse event; FDA: food and drug administration 
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Reporting to the FDA (Model 2) 
 
Table 4.19 presents the adjusted average part-worth utility of each attribute level 
that participants used to decide on reporting the AE to the FDA MedWatch system. The 
significant interaction terms between attributes and the significant covariate of other 
participant’s characteristics were included in the model. The only interaction terms 
retained in a backward selection model that included all attributes, interactions and 
covariates was between “45 years age of patient” and “initiation of DS in the past two 
weeks”. The covariates that were retained in the backward selection model and were 
included in the adjusted model-2 included “participant’s age category of 50-59 years”, 
“African American ethnicity”, “previous reporting of an AE to the drug manufacturer with 
including a DS in the report”, “primary practice setting in academia”, “overall attitude 
toward the safety of DS”, “overall attitude toward the clinical use of DS”, “other races”, 
“female gender”, “participant’s age category of 60 years or older”, “primary practice 
setting in community pharmacy”, “participant’s age category of 30-39 years”, 
“participant’s age category of 40-49 years”, “did not encounter a patient with a suspected 
DS-AE”, “no previous reporting of an AE to the DS manufacturer”, “primary practice 
setting in ambulatory healthcare facility”, and “previous reporting of an AE to the FDA 
MedWatch system without including a DS in the report”; (Appendix F). 
After including the significant interaction terms and covariates, the significance 
levels the attributes did not change. The size of some part-worth utilities and the 
importance of the some attributes, however, resulted in some small changes after including 
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the significant interaction terms and covariates (Table 18 and Table 19). The importance of 
other attributes resulted in small changes (Figure 4.11 and Figure 4.12). The ranges of part-
worth utilities resulted in small changes as well after including the significant interaction 
terms and covariates (Table 4.20 and Table 4.21). Overall, there was a minimal 
modification on this model after including the significant interaction terms and covariates.  
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Table 4.19 – Results of the conjoint analysis for reporting to the FDA MedWatch 
system (model 2) 
 
Attributes Levels 
General Model 
Part Worth 
β (95% CI) SE p-value 
1. Age of patient a. 25 years 0.04 (Reference*) — — 
b. 45 years -0.07 (-0.20, 0.06) 0.07 0.303 
c. 70 years 0.03 (-0.10, 0.16) 0.07 0.637 
2. Initiation of DS† a. Within the past 2 weeks 0.13 (-0.04, 0.22) 0.05 0.006 
b. About 6 months ago -0.13 (Reference*) — — 
3. Time since last 
change of drug 
therapy† 
a. Within the past 2 weeks 0.10 (0.00, 0.20) 0.05 0.042 
b. About 6 months ago -0.10 (Reference*) — — 
4. Evidence of DS-
AE† 
a. Consistent evidence in the 
literature 0.55 (Reference*) — — 
b. Inconsistent (or mixed) 
evidence 0.09 (-0.05, 0.22) 0.07 0.211 
c. No evidence in the 
literature -0.64 (-0.77, -0.51) 0.07 <0.001 
5. Outcome of the 
DS-AE† 
a. Self-limiting -0.88 (Reference*) — — 
b. Required outpatient/ER 
visit -0.18 (-0.34, -0.02) 0.08 0.026 
c. Required hospitalization 0.20 (0.04, 0.35) 0.08 0.014 
d. Resulted in permanent 
disability 0.83 (0.66, 1.00) 0.09 <0.001 
Constant   3.55 (2.54, 4.56) 0.51 <0.001 
Number of obs 
Number of groups 
Pseudo R2 
Chi Square 
p-value 
750 
195 
33.60% 
358.40 
<0.0001 
   
DS: dietary supplement; AE: adverse event; CI: confidence interval; ER: emergency room; 
SE: standard error 
*This was calculated from the model using effects coding 
**No significant interaction terms were retained at p = 0.05 level  
† The attribute is significantly different from zero at p = 0.05 level (Table 4.23) 
Note: see appendix F for complete results with the covariates that were retained in this 
model 
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Figure 4.12 – Relative importance of attributes for reporting to the FDA MedWatch 
system (model 2) 
2.92% 
7.55% 
5.83% 
34.70% 
49.00% 
0% 20% 40% 60% 
Age of patient 
Duration on DS 
Change in therapy 
Evidence of AE 
Outcome of AE 
Relative Importance 
 
 
109 
 
Table 4.20 – Utility ranges of attributes for reporting to prescriber, drug 
manufacturer, dietary supplement manufacturer, and FDA MedWatch system 
(model 1) 
 
Attributes 
Utility Range 
Prescriber 
Drug 
manufacturer 
DS 
manufacturer 
FDA 
MedWatch 
system 
1. Age of patient 0.10 0.11 0.17 0.10 
2. Initiation of DS 0.19 0.27 0.09 0.23 
3. Time since last change 
of drug therapy 0.16 0.17 0.20 0.23 
4. Evidence of DS-AE 1.46 0.85 0.81 1.14 
5. Outcome of the DS-AE 1.28 1.58 1.43 1.67 
DS: dietary supplement; AE: adverse event; FDA: food and drug administration 
 
 
 
 
Table 4.21 – Utility ranges of attributes for reporting to prescriber, drug 
manufacturer, dietary supplement manufacturer, and FDA MedWatch system 
(model 2) 
 
Attributes 
Utility Range 
Prescriber 
Drug 
manufacturer 
DS 
manufacturer 
FDA 
MedWatch 
system 
1. Age of patient 0.13 0.13 0.19 0.10 
2. Initiation of DS 0.18 0.29 0.11 0.26 
3. Time since last change 
of drug therapy 0.09 0.15 0.19 0.20 
4. Evidence of DS-AE 1.51 0.91 0.84 1.19 
5. Outcome of the DS-AE 1.37 1.62 1.48 1.67 
DS: dietary supplement; AE: adverse event; FDA: food and drug administration 
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Table 4.22 – Level of significance of attributes for reporting to prescriber, drug 
manufacturer, dietary supplement manufacturer, and FDA MedWatch system 
(model 1) 
 
Attributes 
Utility Range 
Chi2 (p-value) 
Prescriber 
Drug 
manufacturer 
DS 
manufacturer 
FDA 
MedWatch 
system 
6. Age of patient 1.67  
(0.4344) 
1.09  
(0.5803) 
2.62 
(0.2694) 
0.90 
(0.6364) 
7. Initiation of DS 4.09 
(0.0430) 
9.44  
(0.0021) 
1.24 
(0.2648) 
6.50 
(0.0108) 
8. Time since last change 
of drug therapy 
2.82   
(0.0929) 
3.63 
(0.0567) 
4.95  
(0.0261) 
6.14  
(0.0132) 
9. Evidence of DS-AE 168.52 
 (<0.000) 
65.34 
 (<0.000) 
61.33 
 (<0.000) 
108.80  
(<0.000) 
10. Outcome of the DS-AE 98.25  
(<0.000) 
153.82  
(<0.000) 
136.68 
(<0.000) 
169.97  
(<0.000) 
DS: dietary supplement; AE: adverse event; FDA: food and drug administration 
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Table 4.23 – Level of significance of attributes for reporting to prescriber, drug 
manufacturer, dietary supplement manufacturer, and FDA MedWatch system 
(model 2) 
 
Attributes 
Utility Range 
Prescriber 
Drug 
manufacturer 
DS 
manufacturer 
FDA 
MedWatch 
system 
6. Age of patient 2.39  
(0.3032) 
1.50  
(0.4735) 
3.07  
(0.2150) 
1.06 
(0.5872) 
7. Initiation of DS 3.75  
(0.0528) 
10.28  
(0.0013) 
1.56  
(0.2116) 
7.60 
(0.0058) 
8. Time since last change 
of drug therapy 
0.85  
(0.3559) 
2.61 
(0.1061) 
4.46  
(0.0348) 
4.12 
(0.0423) 
9. Evidence of DS-AE 170.08 
 (<0.000) 
70.10 
 (<0.000) 
60.09 
 (<0.000) 
108.62 
(<0.000) 
10. Outcome of the DS-AE 107.45 
(<0.000) 
150.46 
(<0.000) 
133.84 
(<0.000) 
157.58 
(<0.000) 
DS: dietary supplement; AE: adverse event; FDA: food and drug administration 
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Validation 
 
The holdout validation method did not yield good results. In this method, the 
average predicted responses for the holdout proﬁle were obtained using each of the final 
regression models that were developed using the five attributes, the significant interaction 
terms and covariates. The average difference between the observed responses for the 
holdout proﬁle and the predicted responses was examined for each profile. The average 
difference was not significantly different from zero (4.31- 4.25=0.06; p = 0.2287) for the 
reporting to the prescriber (Model 2). The average difference was not significantly 
different from zero (2.98- 2.93=0.06; p = 0.2621) for the reporting to drug manufacturer 
(Model 2). The average difference was significantly different from zero (2.73- 2.91= -0.18; 
p = 0.0004) for the reporting to DS manufacturer (Model 2). The average difference was 
significantly different from zero (3.22- 4.25= -1.02; p = < 0.000) for the reporting to FDA 
(Model 2). The models were not good in predicting reporting responses to DS 
manufacturer and FDA. However, prediction of responses was not the general purpose of 
this study. The purpose of this study was understating the importance of the five selected 
attributes on participating pharmacists’ decision to report a DS-AE. 
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CHAPTER 5: DISCUSSION 
 
 
 
 
This study attempted to describe practicing pharmacists’ attitudes toward the safety 
and clinical use of DS, level of knowledge about DS and DS regulations and other 
characteristics including the usage, availability and usefulness of DS information 
resources. It also attempted to determine the importance of selected attributes that 
influence a pharmacist’s decision to report a DS related AE to different agencies using a 
CA approach. Five attributes were used in the conjoint models; the effect of other 
characteristics was also considered. 
 
Participant Characteristics 
 
A total of 206 practicing pharmacists finished the questionnaire with complete 
responses. The response rate in this study was estimated to be 27% which may seem low 
but is relatively good for an online survey.82 The response rate in a recent study by Claudia 
et al. using online surveys in a national sample of medical ofﬁce managers and physicians 
to evaluate their preferences for seven vaccine presentation attributes using a CA approach 
was 13.5%.81 Another national online survey study to determine institutional policies and 
practices related to the use of DS resulted in a response rate of 25%.99 The response rate 
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was 27% in an online survey study to identify and evaluate commonly used drug 
information resources by pharmacists in Singapore.83 
The majority of the participants in this study were female (63.86%), Caucasian 
(83.09%) and were 30 to 59 years of age (80.00%). The fact that more females participated 
in this study than male is not consistent with other survey studies in a similar population.77, 
80 The majority of participants were practicing in inpatient pharmacy settings (46.34%); 
this is likely due to the fact that the population of this study were preceptors of PharmD 
students who were primarily practicing in a hospital setting. In other similar studies, the 
majority of pharmacists were practicing in a community/outpatient pharmacy setting.16, 80, 
100 
This study found that the reporting rate of DS related AE is low. Less than 10% of 
participants indicated that they had included a DS in their AE report to the FDA 
MedWatch system and to a drug manufacturer. The reporting rate of DS related AE to the 
DS manufacturer was even less (5.34%). This low reporting rate of DS related AE in 
general might be due to participants’ lack of knowledge of DS regulations. Also, the 
majority of participants did not know that the FDA requires the manufacturer (i.e., the 
entity that is manufacturing and labeling for initial sale or the entity that is repackaging 
products for sale) to report all serious DS related AEs to the FDA within 15 days. These 
findings are consistent with the FDA reports that about 38% of DS related AE reports were 
voluntary reports including all mild, moderate and serious DS related AE submitted by 
consumers and healthcare practitioners to the FDA. The majority of DS related AE reports 
(62%) were mandatory reports of serious AEs submitted by DS manufacturer.15 
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The percentage of participants who had completed formal training related to DS or 
CAM is about 20%. That is relatively low considering that about 40% of participants have 
encountered a patient with a suspected DS related AE. Our finding is lower than Chang et 
al. who found that about 45% of a convenience sample of practicing pharmacists attending 
regional meetings had previous continuing education on herbal medications.100 Another 
study found that about 56% of practicing pharmacists in California had previous training 
on CAM.101 In a study by Olatunde et al., pharmacy leaders were interviewed to assess 
their perceptions of pharmacists' professional roles and responsibilities about NHP. 
Pharmacy leaders described pharmacists' professional roles and responsibilities for NHPs 
as similar to those for OTC drugs and believed that pharmacists should have a basic level 
of knowledge about NHPs and NHP regulations. They also stated that pharmacy managers 
should provide additional training to ensure that their pharmacists have sufficient 
knowledge of NHPs sold in the pharmacy.102 The low percentage of practicing pharmacists 
who completed formal training on DS might indicate the shortage of such courses and 
programs that are available for pharmacists and other healthcare professionals as 
continuing education credits.  
The overall participants’ attitudes toward the clinical use of DS tended to be 
positive (41.10%) or neutral (25.90%). Their overall attitude toward the safety of DS, on 
the other hand, tended to be negative (41.50%) or neutral (32.10%). A systematic review of 
19 studies of U.S. and Canadian pharmacists reported inconsistent attitudes of pharmacists 
toward the clinical efficacy and safety of DS. Both positive and negative attitudes were 
reported and no clear conclusion was drawn due to heterogeneity of the included study 
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results and lack of a consistent definition of DS.71 The finding of this study related to 
pharmacist’s attitudes toward the efficacy and safety of DS contradict the findings of two 
previous U.S. studies.16, 101 Dolder et al. found that about 50% of practicing pharmacists in 
California had a negative attitude toward safety of DS.101 About 19% of practicing 
pharmacists in Minnesota believed that HNP were effective for clinical use and about 50% 
believed they were safe.16 This study found that formal training related to DS or CAM 
significantly affected pharmacist’s overall attitude toward the clinical use and safety of DS. 
Formal training increased positive attitudes toward the clinical use of DS and increased the 
negative attitude regarding the safety of DS. This might be due to formal training 
increasing pharmacist’s overall awareness of the evidence of the effectiveness of some DS 
products, on one hand, as well as increasing pharmacist’s awareness of the potential risks 
associated with the consumption of some DS products related to DS contamination or 
interactions with other medication.  
Evaluation of DS knowledge in this study was not comprehensive and might not 
have correctly measured the actual participants’ knowledge about DS. The ability of 
practicing pharmacist to correctly identify a DS product was evaluated. The average DS 
identification quiz score was 80%. This is not consistent with the findings of the only other 
identified U.S. study that assessed pharmacist’s actual knowledge of DS. The average 
score in that study was less than 50%. The significant difference between the average score 
in that study and this study may be due to the difference in the comprehensiveness and 
difficulty level of the two tests. The test in the aforementioned study was more 
comprehensive. Also, participants of that study were instructed to select ''I don't know'' 
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instead of guessing an answer.71 More research is needed to assess pharmacist and other 
healthcare professional knowledge about the use of DS. The assessment should include 
knowledge about DS indication, effectiveness, dosage, storage, side effects, DS-DS 
interactions, and DS-drug interactions. 
The average pharmacist’s knowledge score on DS regulations quiz was about 46% 
in this study. Ashar et al. evaluated physician knowledge of DS regulation and the AE 
reporting process. The average knowledge score was poor (59%).54 Another study by the 
same group found that the average knowledge score of 15 medical residents of DS 
regulation was about 60%.78 No studies evaluated pharmacist knowledge of DS 
regulations. Courses on DS regulation could increase healthcare professionals’ awareness 
of such regulation and the reporting process of DS related AE. Physicians’ average scores 
dramatically increased to from 59% to 91% after completing an online course about DS 
regulation. 
 
DS Information Resources 
 
The most commonly used DS information resources according to the current study 
were Lexi-Comp® (69.90%), Facts and Comparisons: Review of Natural Products 
(61.65%), Natural Medicines Comprehensive Database (by Pharmacist’s Letter) (57.77%), 
and Micromedex®: AltMedDex (47.57%). These four most commonly used resources 
were those most commonly held at practice site. These findings are consistent with Bazzie 
et al. study where they found the most commonly used DS information resources in acute 
care facilities were the internet (66%), Natural Medicines Comprehensive Database (34%), 
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and Micromedex®: AltMeDex (23%).99 The most commonly available resources in 
another study were different than our finding; Nathan et al. found that the most commonly 
used DS information resources in community pharmacies in New York and New Jersey 
were the PDR for Herbal Medicines (42.5%), The Review of Natural Products (20.0%), 
and the Web site of the National Center for Complementary and Alternative Medicine 
(12.5%).61 
Publication dates of popular DS information resources varied considerably. Three 
of the most commonly used resources in this study were fairly timely updated: Lexi-
Comp® is an online recourse that is updated automatically on daily bases and 
Micromedex®: AltMeDex is an electronic resource that is updated annually. The print 
version of Natural Medicine Comprehensive Database is updated annually, and portions of 
The Review of Natural Products are updated monthly. The timeliness of these resources is 
important, as information in this field is changing rapidly. Also, the three most commonly 
used resources were both available in electronic formats, possibly indicating that the ability 
to easily search by a variety of common names, as well as by popular brand-name 
formulations, may be important factors for administrators in selecting information 
resources. Resources available in electronic formats may also be preferred because their 
content is updated more frequently than that of print texts. 
All of the resources were relatively useful with the minimum score of 3.03 and 
maximum score 4.21 out of 5. The most useful resource was Natural Medicines 
Comprehensive Database followed by The Complete German Commission E Monographs 
and Facts and Comparisons: Review of Natural Products. However, the second most useful 
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resource, The Complete German Commission E Monographs, is relatively old. It was 
published in 1998 and is a translation of an earlier work. No other studies evaluated the 
usefulness of these resources as source of information about DS. These resources might be 
different in providing good summaries of available literature, addressing the possible side 
effects, contraindications, DS-drug interactions, or DS-DS interactions. Further evaluation 
of the usefulness of DS information resources in answering specific DS related questions is 
needed. 
 
Conjoint Analysis 
 
To the best of our knowledge, there has been no previous research done to identify 
factors affecting a pharmacist’s decision in reporting a DS related AE to the FDA 
MedWatch system or other agencies. Practicing pharmacists were selected because they 
could be among the first line in detecting and reporting AEs related to the use of DS. 
Moreover, DS consumers consider pharmacists a reliable and knowledgeable source of 
information and advice about DS. In a U.S. study, 37% of respondents viewed 
pharmacists’ advice CAM as important and 30 % of them relied on pharmacists as a source 
of information about the choices of DS and herbal products.19, 103 
The CA portion of this study revealed that the most important attribute was the 
evidence supporting the AE in the literature for reporting to the prescriber. The second 
most important attribute was the outcome of the AE. The first and second most important 
attribute were opposite for reporting to the drug manufacturer, DS manufacturer and FDA 
MedWatch system. The outcome of the AE the most important attribute and the evidence 
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supporting the AE in the literature was the second most important. In general, all other 
attributes were much less important than these two attributes. This might indicate that 
practicing pharmacists think they need to provide strong evidence when calling the 
prescribing provider to report an AE. That also might indicate that the pharmacists 
perceive the outcome of the AE to be more important to the drug manufacturer, DS 
manufacturer, and FDA MedWatch system than the evidence supporting the AE when 
deciding whether to submit the AE report.  
The relationship between the attributes levels were as expected for most of the 
attributes. The younger age category (25 years) and the elder age category (70 years) have 
higher utilization on pharmacists’ decision than the middle age category (45 years). The 
closer initiation time of DS and change of drug therapy (2 weeks ago) have higher 
utilization on pharmacists’ decision than the longer initiation of DS and change of drug 
therapy (6 months ago). Also, the permanent disability as the outcome of the AE has 
higher utilization on pharmacists’ decision than the self-limited outcome. 
It was expected that participants would place more importance on absence of 
evidence of the AE in the literature in reporting an AE to any place; especially to the FDA 
MedWatch system. All models, however, indicated the opposite. Participants cited 
availability of consistent evidence in the literature significant compared to the absence of 
evidence in reporting an AE to all places. This might indicate the need for more evidence 
on the efficacy and safety of DS. It might also indicate the need to educate professionals 
that absence of evidence in the literature maybe another compelling reason to submit an 
AE report. The importance that participants gave to the levels of the outcome of the AE 
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was as hypothesized. Participants reported less importance to the self-limited AE that 
resolved upon discontinuation of the DS and more importance to the serious AE that 
resulted in permanent disability. 
Reporting of DS-AE to any place might be influenced by the propensity to report 
characteristic of the participant. Some people are "reporters" and some are not "reporters". 
This general reporting issue was assessed by asking participants if they had ever reported 
an AE to drug manufacturer, DS manufacturer or FDA MedWatch system. Reporting 
characteristic variables were included as covariates in the adjusted models in estimating the 
importance of the five selected attributes. Future research is needed to further examine the 
effect of propensity to report characteristic of a professional on decision to report a DS-
AE. 
The models did not perform well in predicting the holdout profile responses. 
However, models were better in predicting responses of the study profiles. The correlation 
between the predicted and actual responses was around 50% in all models. Generalization 
of these results should be made with care. Selection of a sample from the state of Virginia 
and from specific population of preceptors of PharmD student limits generalizability. The 
statistically insigniﬁcant coefﬁcients of some attributes still might be of importance to the 
participants, but they merely do not perceive a detectable difference.104 
 
Implications 
 
As mentioned before, the reporting rate of AE related to DS by healthcare 
professionals to the FDA MedWatch system is as low as 1 % given their high consumption 
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rate in the United States.48 The reporting to other agencies such as PCCs and DS 
manufacturers is most likely to be lower than expected. On the other hand the FDA 
MedWatch system does not have strict premarketing regulations and considers these 
products as generally safe unless proven otherwise through its MedWatch system. 
Identifying the important factors influencing pharmacist’s decisions to report a DS 
related AE might be helpful for authorities in establishing policies and regulations of the 
reporting process of DS related AE. This study found that the most important factors in 
reporting a DS related AE were the evidence supporting the AE in the literature and the 
severity of the AE outcome. However, the amount of evidence in the literature about DS is 
relatively low, likely in part, because the FDA does not require DS manufacturer to submit 
premarketing safety and efficacy studies. Also NIH and other Federal institutions fund 
relatively fewer DS studies compared to conventional drug studies. This study indicates 
that there is a need for more DS evidence in the literature to improve the reporting of DS 
related AE among pharmacists. Practicing pharmacist’s knowledge of DS regulation is 
poor as indicated by this and other studies.21, 36, 54, 55 Developing and providing education 
on DS for pharmacy students as well as for practicing pharmacists could be beneficial 
because this may improve their knowledge about DS and potentially increase their 
reporting of DS related AEs. The literature indicated that pharmacists themselves do not 
perceive their knowledge to be adequate and would like to receive additional education on 
DS.16, 103  
The description of DS information resource usage, availability and usefulness could 
be used by healthcare systems and community pharmacy leaders as guidance in selecting 
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the best DS information resources for their institutions. According to the findings of this 
study, the most commonly used DS information recourses are not necessarily the most 
useful ones. Findings of this study might be used to improve the availability and usage of 
the most useful DS resources. 
 
Strengths 
 
One strength of the study was the assessment of five attributes related to patient 
factors, AE outcome, and other concomitant medications that were hypothesized to 
influence a pharmacist’s decision in reporting a DS related AE. Another strength is the 
assessment of participating pharmacist’s attitude, knowledge and other characteristics. This 
study also sought to analyze the impact of these characteristics as secondary factors on the 
utility and importance of the five primary attributes. Although the entire questionnaire had 
not been formally validated, the knowledge section was based on items that had been 
validated in previous studies.28, 29, 78 Additionally, the results were generally intuitively 
correct and go along with the published literature. For instance, women had more positive 
attitude toward DS than men. This might lends some credibility and validity to the results 
of this study. 
 
Limitations 
 
This project has some limitations related to the sampling frame, validity of the 
design, validity the method and the instrument used in this study. Since the study 
population was limited to the Commonwealth of Virginia, the external validity of the study 
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and the generalizability of the findings to other states might be limited. In addition, the 
generalizability of our findings to other healthcare providers might be limited because our 
sampling frame is limited to practicing pharmacists. Additionally, the majority of 
respondents were female and Caucasian thus limiting generalizability to males and other 
ethnicities. The external validity of the study might be limited because the study sample 
was not a random sample. It is also possible that there may be unobserved factors 
introducing a systematic bias. The use of pharmacy preceptors as the population of interest 
might have added potential selection bias because these individuals might be more in tune 
with reporting than the general population of practicing pharmacists. A convenience 
sample was used to reduce the complexity and difficulty of the design. It was, also, 
difficult and unfeasible to select a nationwide random sample of practicing pharmacists 
since no known or readily available list of all practicing pharmacists in the nation exists. 
Death as the most extreme outcome was not included as one of the levels because 
that would have required a different scenario template that could have confused the 
respondents. The omission of death as a potential outcome could confound the responses 
as the respondents could have thought that the “resulted in permanent disability” is not the 
most extreme outcome. This issue was extensively discussed with a group of practicing 
pharmacists in the process of developing the questionnaire. After discussion, it was 
concluded that either death or permanent disability would be sufficiently the same from 
this standpoint. The responses could however be different if death were included. 
Some of the variables that are not the focus of this study such as patient gender and 
ethnicity were held constant to keep the scenarios concise and manageable by respondents. 
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Clinical information that could be important in such decision making is not provided in the 
scenarios. This was done to reduce the complexity of the scenarios and to make the choice 
task manageable by the respondents. It has been suggested that up to six variables could be 
handled by respondents in one scenario.96 These issues might limit the ability of these 
scenarios to reflect the actual pharmacist’s decisions to report DS-AE. Another limitation 
could be related to the exclusion of pregnant and breastfeeding women. While including 
this group might have influenced DS-AE reporting given risk to the infant, it would have 
introduced another level of complexity that could further complicate the scenarios. To 
avoid the confusion that might happen in the minds of the participants when they consider 
such population, male gender was used rather than female gender or both male and female 
gender. 
Due to the nature of this type of preference study, it is unknown whether or not the 
responses to hypothetical case scenarios’ questions would reflect what respondent might 
actually do in a real situation. The purpose of adding the holdout scenarios was to help 
assure the validity of the responses and to minimize this limitation.88, 98, 105 However, the 
model was not good in predicting responses for the holdout profiles. The general purpose 
of this study was understating the importance of the five selected attributes on participating 
pharmacists’ decision to report a DS-AE. It was not proposed to predict responses in other 
population.  
As a general limitation of the preference studies such as this study, there is a 
potential for domination of few attributes in making a decision or a preference. Sometimes 
individuals for various reasons such as the inclusion of too many attributes or lack of 
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understanding of the situation or just for their general decision-making process will only 
focus on one or two attributes. These attributes then dominate the other attributes. In this 
study, the evidence of AE and the outcome of the AE seem to be dominant attributes over 
the other attributes. Future studies might be needed to look at this potential phenomenon. 
The items examining the pharmacist’s knowledge about DS and their regulation 
were developed based on previous studies that assessed healthcare professional’s 
knowledge about DS as well as group discussions with practicing pharmacists.16, 28, 29, 54, 71, 
80, 100 While the instrument used in this study was pre-tested to identify any potential 
problems, it’s validity was not further examined. Additionally, because it was not a central 
focus of the study, the DS identification quiz was not comprehensive and may not have 
adequately measured the participant’s knowledge about DS. 
 
Future Directions 
 
The findings from the descriptive portion of this study provide useful information 
on the general characteristics of practicing pharmacists about DS AE reporting that can be 
used as a foundation for generating hypotheses for future research in pharmacists and other 
healthcare professionals as well as consumers of DS. This study also attempted to evaluate 
attributes affecting pharmacist decision making in reporting an AE related to DS uses. 
Future studies could be conducted to evaluate attributes influencing these decisions in 
physicians and other healthcare professionals. No other similar studies were identified in 
the literature. Further research is needed to further investigate the main objectives of this 
study and to further confirm its findings. This research also highlights the need to develop 
 
 
127 
 
educational tools and strategies to improve the knowledge of pharmacists related to DS and 
DS regulation. 
 
Conclusion 
 
The overall attitude of practicing pharmacists was relatively positive for the clinical 
use of DS but relatively negative for safe of DS. Formal training on DS is associated with 
better knowledge regarding DS regulation. Very few people included DS in an ADE report 
to either the FDA MedWatch system or the drug manufacturer and almost none had ever 
reported an AE to a DS manufacturer. The average knowledge score of DS identification 
was relatively good but is low for DS regulation knowledge. More comprehensive DS 
knowledge assessment of pharmacists and other healthcare professionals is needed. The 
usefulness and availability of DS information resources are variable. Lexi-Comp® is 
widely used and available information resource and the Natural Medicines Comprehensive 
Database is the most useful information resource. Most of these finding go along with 
available literature. 
In general, the part worth values and the importance for the evidence supporting the 
AE and the severity of the outcome of the AE attributes were much higher than those of 
age of patient, initiation of DS and time since last modification of drug therapy attributes. 
The important level of the attributes that a pharmacist considered in the decision to report a 
DS-AE to the drug manufacturer, DS manufacturer and FDA MedWatch system classified 
into three levels. Outcome of the AE had high importance level, the evidence of the AE 
had medium importance level, and the remaining three attributes (age of patient, initiation 
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of DS and time since last modification of drug therapy) had low importance level. The 
importance levels of the attributes classified into two levels only when reporting to the 
prescriber. Both evidence of the AE and outcome of the AE had high importance level and 
the remaining three attributes had low importance level. 
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Table A.1 – Full listing of the study profiles used in final conjoint questionnaire 
sorted by their rank score for reporting to the prescriber 
 
 
Block 
Attributes  
Age of 
patient 
Initiation 
of DS 
Change of 
therapy Evidence Outcome Rank† 
1.  L3 25 2W 2W KN DIS 1.47 
2.  E2 70 9M 2W KN DIS 1.25 
3.  M2 45 2W 9M KN DIS 1.2 
4.  I3 25 9M 9M KN DIS 1.19 
5.  N4 45 9M 2W KN DIS 1.12 
6.  G1 25 2W 9M KN HO 1.01 
7.  K4 70 2W 9M KN HO 0.97 
8.  B3 45 2W 2W KN HO 0.94 
9.  F4 25 2W 2W KN ER 0.93 
10.  B4 25 9M 2W KN HO 0.93 
11.  G3 70 9M 2W KN HO 0.89 
12.  A4 70 2W 2W RPT DIS 0.86 
13.  E1 25 2W 9M RPT DIS 0.8 
14.  I1 45 2W 9M KN ER 0.66 
15.  J1 45 9M 9M KN HO 0.66 
16.  B1 70 9M 9M KN ER 0.61 
17.  D2 45 9M 2W KN ER 0.58 
18.  C4 70 9M 9M RPT DIS 0.58 
19.  M3 45 9M 2W RPT DIS 0.55 
20.  F1 25 2W 2W RPT HO 0.54 
21.  E4 70 9M 2W RPT HO 0.32 
22.  H2 70 2W 2W RPT ER 0.32 
23.  N2 45 2W 9M RPT HO 0.27 
24.  M4 25 2W 9M RPT ER 0.26 
25.  A2 25 9M 9M RPT HO 0.26 
26.  J2 45 2W 2W RPT ER 0.19 
27.  G2 25 9M 2W RPT ER 0.18 
28.  C2 70 2W 2W KN SL 0.05 
29.  A1 45 9M 9M RPT ER -0.09 
30.  K3 25 9M 2W KN SL -0.09 
31.  I2 70 2W 9M UNK DIS -0.18 
32.  D4 45 2W 9M KN SL -0.18 
33.  C3 45 2W 2W UNK DIS -0.21 
34.  M1 25 9M 2W UNK DIS -0.22 
35.  H4 70 9M 9M KN SL -0.23 
36.  E3 25 2W 2W UNK HO -0.4 
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37.  J4 70 2W 2W UNK HO -0.44 
38.  H3 25 2W 2W RPT SL -0.48 
39.  L4 45 9M 9M UNK DIS -0.49 
40.  B2 25 2W 2W UNK ER -0.58 
41.  G4 70 2W 9M RPT SL -0.62 
42.  D3 45 2W 9M UNK HO -0.67 
43.  J3 70 9M 2W RPT SL -0.7 
44.  A3 70 2W 9M UNK ER -0.72 
45.  F3 70 9M 9M UNK HO -0.72 
46.  K1 45 9M 2W UNK HO -0.75 
47.  N3 25 9M 9M RPT SL -0.76 
48.  I4 70 9M 2W UNK ER -0.8 
49.  L2 45 9M 2W RPT SL -0.83 
50.  H1 25 9M 9M UNK ER -0.86 
51.  F2 45 9M 2W UNK ER -0.93 
52.  K2 70 2W 2W UNK SL -1.46 
53.  L1 25 2W 9M UNK SL -1.52 
54.  N1 45 2W 2W UNK SL -1.59 
55.  D1 25 9M 2W UNK SL -1.65 
56.  C1 45 9M 9M UNK SL -1.87 
25: 25 years; 45: 45 years; 70: 70 years; 2W: 2 months ago; 9M: 9 months ago; KN: 
Consistent evidence in the literature; RPT: inconsistent (or mixed) evidence; UNK: no 
evidence in the literature; SL: self-limiting and resolved upon discontinuation of dietary 
supplement; ER: required an ER visit; HO: required hospitalization; DIS: resulted in 
permanent disability. 
†Is the sum of part-worth utilities of each profile 
 
 
146 
 
Table A.2 – Full listing of the study profiles used in final conjoint questionnaire 
sorted by their rank score for reporting to the drug manufacturer 
 
 
Block 
Attributes  
Age of 
patient 
Initiation 
of DS 
Change of 
therapy Evidence Outcome Rank† 
1.  L3 25 2W 2W KN DIS 1.50 
2.  M2 45 2W 9M KN DIS 1.24 
3.  A4 70 2W 2W RPT DIS 1.23 
4.  E2 70 9M 2W KN DIS 1.23 
5.  N4 45 9M 2W KN DIS 1.10 
6.  E1 25 2W 9M RPT DIS 1.07 
7.  I3 25 9M 9M KN DIS 1.06 
8.  M3 45 9M 2W RPT DIS 0.82 
9.  C4 70 9M 9M RPT DIS 0.79 
10.  B3 45 2W 2W KN HO 0.64 
11.  K4 70 2W 9M KN HO 0.61 
12.  G1 25 2W 9M KN HO 0.60 
13.  F4 25 2W 2W KN ER 0.48 
14.  C3 45 2W 2W UNK DIS 0.48 
15.  G3 70 9M 2W KN HO 0.47 
16.  F1 25 2W 2W RPT HO 0.46 
17.  B4 25 9M 2W KN HO 0.46 
18.  I2 70 2W 9M UNK DIS 0.45 
19.  M1 25 9M 2W UNK DIS 0.30 
20.  I1 45 2W 9M KN ER 0.22 
21.  H2 70 2W 2W RPT ER 0.21 
22.  N2 45 2W 9M RPT HO 0.20 
23.  J1 45 9M 9M KN HO 0.19 
24.  E4 70 9M 2W RPT HO 0.19 
25.  J2 45 2W 2W RPT ER 0.08 
26.  D2 45 9M 2W KN ER 0.08 
27.  B1 70 9M 9M KN ER 0.05 
28.  M4 25 2W 9M RPT ER 0.04 
29.  L4 45 9M 9M UNK DIS 0.03 
30.  A2 25 9M 9M RPT HO 0.02 
31.  G2 25 9M 2W RPT ER -0.10 
32.  C2 70 2W 2W KN SL -0.10 
33.  J4 70 2W 2W UNK HO -0.15 
34.  E3 25 2W 2W UNK HO -0.16 
35.  A1 45 9M 9M RPT ER -0.36 
36.  D4 45 2W 9M KN SL -0.38 
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37.  H3 25 2W 2W RPT SL -0.40 
38.  K3 25 9M 2W KN SL -0.41 
39.  D3 45 2W 9M UNK HO -0.43 
40.  B2 25 2W 2W UNK ER -0.43 
41.  G4 70 2W 9M RPT SL -0.54 
42.  H4 70 9M 9M KN SL -0.55 
43.  K1 45 9M 2W UNK HO -0.57 
44.  A3 70 2W 9M UNK ER -0.57 
45.  F3 70 9M 9M UNK HO -0.59 
46.  J3 70 9M 2W RPT SL -0.68 
47.  I4 70 9M 2W UNK ER -0.71 
48.  L2 45 9M 2W RPT SL -0.80 
49.  F2 45 9M 2W UNK ER -0.84 
50.  N3 25 9M 9M RPT SL -0.85 
51.  H1 25 9M 9M UNK ER -0.88 
52.  K2 70 2W 2W UNK SL -1.02 
53.  N1 45 2W 2W UNK SL -1.14 
54.  L1 25 2W 9M UNK SL -1.18 
55.  D1 25 9M 2W UNK SL -1.32 
56.  C1 45 9M 9M UNK SL -1.59 
25: 25 years; 45: 45 years; 70: 70 years; 2W: 2 months ago; 9M: 9 months ago; KN: 
Consistent evidence in the literature; RPT: inconsistent (or mixed) evidence; UNK: no 
evidence in the literature; SL: self-limiting and resolved upon discontinuation of dietary 
supplement; ER: required an ER visit; HO: required hospitalization; DIS: resulted in 
permanent disability. 
†Is the sum of part-worth utilities of each profile 
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Table A.3 – Full listing of the study profiles used in final conjoint questionnaire 
sorted by their rank score for reporting to the DS manufacturer 
 
 
Block 
Attributes  
Age of 
patient 
Initiation 
of DS 
Change of 
therapy Evidence Outcome Rank† 
1.  L3 25 2W 2W KN DIS 1.38 
2.  E2 70 9M 2W KN DIS 1.37 
3.  N4 45 9M 2W KN DIS 1.18 
4.  M2 45 2W 9M KN DIS 1.10 
5.  A4 70 2W 2W RPT DIS 1.10 
6.  I3 25 9M 9M KN DIS 1.08 
7.  E1 25 2W 9M RPT DIS 0.80 
8.  M3 45 9M 2W RPT DIS 0.79 
9.  C4 70 9M 9M RPT DIS 0.79 
10.  G3 70 9M 2W KN HO 0.59 
11.  B3 45 2W 2W KN HO 0.51 
12.  K4 70 2W 9M KN HO 0.50 
13.  B4 25 9M 2W KN HO 0.49 
14.  C3 45 2W 2W UNK DIS 0.45 
15.  I2 70 2W 9M UNK DIS 0.45 
16.  M1 25 9M 2W UNK DIS 0.43 
17.  G1 25 2W 9M KN HO 0.41 
18.  F4 25 2W 2W KN ER 0.35 
19.  F1 25 2W 2W RPT HO 0.21 
20.  J1 45 9M 9M KN HO 0.20 
21.  E4 70 9M 2W RPT HO 0.20 
22.  D2 45 9M 2W KN ER 0.15 
23.  B1 70 9M 9M KN ER 0.15 
24.  L4 45 9M 9M UNK DIS 0.14 
25.  I1 45 2W 9M KN ER 0.07 
26.  H2 70 2W 2W RPT ER 0.07 
27.  C2 70 2W 2W KN SL 0.00 
28.  N2 45 2W 9M RPT HO -0.07 
29.  A2 25 9M 9M RPT HO -0.09 
30.  J2 45 2W 2W RPT ER -0.12 
31.  J4 70 2W 2W UNK HO -0.14 
32.  G2 25 9M 2W RPT ER -0.14 
33.  K3 25 9M 2W KN SL -0.21 
34.  M4 25 2W 9M RPT ER -0.23 
35.  E3 25 2W 2W UNK HO -0.24 
36.  H4 70 9M 9M KN SL -0.30 
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37.  D4 45 2W 9M KN SL -0.38 
38.  A1 45 9M 9M RPT ER -0.43 
39.  K1 45 9M 2W UNK HO -0.44 
40.  F3 70 9M 9M UNK HO -0.45 
41.  H3 25 2W 2W RPT SL -0.49 
42.  B2 25 2W 2W UNK ER -0.49 
43.  J3 70 9M 2W RPT SL -0.50 
44.  I4 70 9M 2W UNK ER -0.50 
45.  D3 45 2W 9M UNK HO -0.53 
46.  G4 70 2W 9M RPT SL -0.58 
47.  A3 70 2W 9M UNK ER -0.58 
48.  L2 45 9M 2W RPT SL -0.69 
49.  F2 45 9M 2W UNK ER -0.69 
50.  N3 25 9M 9M RPT SL -0.79 
51.  H1 25 9M 9M UNK ER -0.79 
52.  K2 70 2W 2W UNK SL -0.84 
53.  N1 45 2W 2W UNK SL -1.03 
54.  D1 25 9M 2W UNK SL -1.05 
55.  L1 25 2W 9M UNK SL -1.14 
56.  C1 45 9M 9M UNK SL -1.34 
25: 25 years; 45: 45 years; 70: 70 years; 2W: 2 months ago; 9M: 9 months ago; KN: 
Consistent evidence in the literature; RPT: inconsistent (or mixed) evidence; UNK: no 
evidence in the literature; SL: self-limiting and resolved upon discontinuation of dietary 
supplement; ER: required an ER visit; HO: required hospitalization; DIS: resulted in 
permanent disability. 
†Is the sum of part-worth utilities of each profile 
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Table A.4 – Full listing of the study profiles used in final conjoint questionnaire 
sorted by their rank score for reporting to FDA 
 
 
Block 
Attributes  
Age of 
patient 
Initiation 
of DS 
Change of 
therapy Evidence Outcome Rank† 
1.  L3 25 2W 2W KN DIS 1.65 
2.  E2 70 9M 2W KN DIS 1.38 
3.  M2 45 2W 9M KN DIS 1.34 
4.  N4 45 9M 2W KN DIS 1.28 
5.  I3 25 9M 9M KN DIS 1.19 
6.  A4 70 2W 2W RPT DIS 1.18 
7.  E1 25 2W 9M RPT DIS 0.98 
8.  B3 45 2W 2W KN HO 0.91 
9.  M3 45 9M 2W RPT DIS 0.82 
10.  G1 25 2W 9M KN HO 0.81 
11.  K4 70 2W 9M KN HO 0.81 
12.  B4 25 9M 2W KN HO 0.75 
13.  G3 70 9M 2W KN HO 0.75 
14.  C4 70 9M 9M RPT DIS 0.72 
15.  F4 25 2W 2W KN ER 0.63 
16.  F1 25 2W 2W RPT HO 0.55 
17.  J1 45 9M 9M KN HO 0.45 
18.  C3 45 2W 2W UNK DIS 0.36 
19.  I1 45 2W 9M KN ER 0.33 
20.  E4 70 9M 2W RPT HO 0.28 
21.  D2 45 9M 2W KN ER 0.27 
22.  I2 70 2W 9M UNK DIS 0.26 
23.  N2 45 2W 9M RPT HO 0.24 
24.  M1 25 9M 2W UNK DIS 0.20 
25.  B1 70 9M 9M KN ER 0.17 
26.  H2 70 2W 2W RPT ER 0.16 
27.  A2 25 9M 9M RPT HO 0.09 
28.  J2 45 2W 2W RPT ER 0.06 
29.  M4 25 2W 9M RPT ER -0.03 
30.  C2 70 2W 2W KN SL -0.03 
31.  G2 25 9M 2W RPT ER -0.09 
32.  L4 45 9M 9M UNK DIS -0.10 
33.  E3 25 2W 2W UNK HO -0.17 
34.  J4 70 2W 2W UNK HO -0.18 
35.  K3 25 9M 2W KN SL -0.29 
36.  D4 45 2W 9M KN SL -0.33 
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37.  A1 45 9M 9M RPT ER -0.39 
38.  D3 45 2W 9M UNK HO -0.48 
39.  H4 70 9M 9M KN SL -0.49 
40.  H3 25 2W 2W RPT SL -0.49 
41.  K1 45 9M 2W UNK HO -0.54 
42.  B2 25 2W 2W UNK ER -0.55 
43.  F3 70 9M 9M UNK HO -0.64 
44.  G4 70 2W 9M RPT SL -0.70 
45.  J3 70 9M 2W RPT SL -0.76 
46.  A3 70 2W 9M UNK ER -0.76 
47.  I4 70 9M 2W UNK ER -0.82 
48.  L2 45 9M 2W RPT SL -0.86 
49.  F2 45 9M 2W UNK ER -0.92 
50.  N3 25 9M 9M RPT SL -0.95 
51.  H1 25 9M 9M UNK ER -1.01 
52.  K2 70 2W 2W UNK SL -1.22 
53.  N1 45 2W 2W UNK SL -1.32 
54.  L1 25 2W 9M UNK SL -1.41 
55.  D1 25 9M 2W UNK SL -1.47 
56.  C1 45 9M 9M UNK SL -1.78 
25: 25 years; 45: 45 years; 70: 70 years; 2W: 2 months ago; 9M: 9 months ago; KN: 
Consistent evidence in the literature; RPT: inconsistent (or mixed) evidence; UNK: no 
evidence in the literature; SL: self-limiting and resolved upon discontinuation of dietary 
supplement; ER: required an ER visit; HO: required hospitalization; DIS: resulted in 
permanent disability. 
†Is the sum of part-worth utilities of each profile 
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Dear participant, 
 
My name is Ali Al-hammad. Currently, I am a PhD student at the VCU School of 
Pharmacy where I am focusing on drug safety issues. One of my particular interests is in 
the safe use of complementary and alternative therapies, such as natural products and 
dietary supplements. My dissertation project is focused on examining the factors that 
influence whether pharmacists report adverse events associated with the use of dietary 
supplements. Identifying these factors may help in developing educational programs to 
improve the awareness of pharmacists and other healthcare professionals about dietary 
supplements and the need for systematic safety surveillance. 
 
I have chosen to use pharmacists who have served as preceptors for VCU pharmacy 
students. Below is a link to an online survey. It should take about 15 minutes to complete. 
All of your responses will be anonymous, and your participation is completely voluntary. 
More information about the project and the survey itself can be found by following the 
link. 
http://vcupharmacy.us2.qualtrics.com/SE/?SID=SV_bloYvnmMf3q4tPS 
 
Your participation would greatly help me complete my dissertation project. If you have 
any questions, please feel free to e-mail me or my advisor, Dr. Spencer Harpe 
(seharpe@vcu.edu). 
 
 
Thank you in advance for helping me with my research project. 
 
 
Best, 
 
Ali Al-hammad 
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First “Thank You/Reminder” E-mail 
 
Dear participant, 
 
About one week ago, you should have received from me an e-mail that contained a link to 
an online survey to help me complete my dissertation research project. As a brief reminder, 
my dissertation project is focused on examining the factors that influence whether 
pharmacists report adverse events associated with the use of dietary supplements. 
Identifying these factors may help in developing educational programs to improve the 
awareness of pharmacists and other healthcare professionals about dietary supplements and 
the need for systematic safety surveillance. 
 
If you have already responded to the survey, I sincerely thank you for your participation. 
You can disregard this e-mail. If you have not yet completed the survey, I would greatly 
appreciate your taking the time (about 15 minutes) to complete the survey by following the 
link below. All of your responses will be anonymous, and your participation is completely 
voluntary. 
http://vcupharmacy.us2.qualtrics.com/SE/?SID=SV_bloYvnmMf3q4tPS 
 
Your participation would greatly help me complete my dissertation project. If you have 
any questions, please feel free to e-mail me or my advisor, Dr. Spencer Harpe 
(seharpe@vcu.edu). 
 
 
Thank you in advance for helping me with my research project. 
 
 
Best, 
 
Ali Al-hammad 
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Second “Thank You/Reminder” E-mail 
 
Dear participant, 
 
About two weeks ago, you should have received from me an e-mail that contained a link to 
an online survey to help me complete my dissertation research project. As a brief reminder, 
my dissertation project is focused on examining the factors that influence whether 
pharmacists report adverse events associated with the use of dietary supplements. 
Identifying these factors may help in developing educational programs to improve the 
awareness of pharmacists and other healthcare professionals about dietary supplements and 
the need for systematic safety surveillance. 
 
If you have already responded to the survey, I sincerely thank you for your participation. 
You can disregard this e-mail. If you have not yet completed the survey, I would greatly 
appreciate your taking the time (about 15 minutes) to complete the survey by following the 
link below. All of your responses will be anonymous, and your participation is completely 
voluntary. 
http://vcupharmacy.us2.qualtrics.com/SE/?SID=SV_bloYvnmMf3q4tPS 
 
Your participation would greatly help me complete my dissertation project. If you have 
any questions, please feel free to e-mail me or my advisor, Dr. Spencer Harpe 
(seharpe@vcu.edu). 
 
 
Thank you in advance for helping me with my research project. 
 
 
Best, 
 
Ali Al-hammad 
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Third “Thank You/Reminder” E-mail 
 
Dear participant, 
 
About two weeks ago, you should have received from me an e-mail that contained a link to 
an online survey to help me complete my dissertation research project. As a brief reminder, 
my dissertation project is focused on examining the factors that influence whether 
pharmacists report adverse events associated with the use of dietary supplements. 
Identifying these factors may help in developing educational programs to improve the 
awareness of pharmacists and other healthcare professionals about dietary supplements and 
the need for systematic safety surveillance. 
 
If you have already responded to the survey, I sincerely thank you for your participation. 
You can disregard this e-mail. If you have not yet completed the survey, I would greatly 
appreciate your taking the time (about 15 minutes) to complete the survey by following the 
link below. All of your responses will be anonymous, and your participation is completely 
voluntary. 
http://vcupharmacy.us2.qualtrics.com/SE/?SID=SV_bloYvnmMf3q4tPS 
 
Your participation would greatly help me complete my dissertation project. If you have 
any questions, please feel free to e-mail me or my advisor, Dr. Spencer Harpe 
(seharpe@vcu.edu). 
 
 
Thank you in advance for helping me with my research project. 
 
 
Best, 
 
Ali Al-hammad 
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Final “Thank You” E-mail 
 
Dear participant, 
 
I sincerely thank you for assisting me with my dissertation research. Your participation 
would greatly help me complete my dissertation project. 
If you have any questions, please feel free to e-mail me or my advisor, Dr. Spencer Harpe 
(seharpe@vcu.edu). 
 
All of your responses will be anonymous, and your participation is completely voluntary. 
 
 
Best, 
 
Ali Al-hammad 
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Table F.1 – Relationship between respondent characteristics and the overall attitudes 
toward the clinical use of DS 
 
 Categories 
Overall Attitude (%) 
p-value Positive 
Somewhat 
positive Neutral 
Somewhat 
negative Negative 
Gender 
n=202       
0.515 
Male 8.22% 31.51% 23.29% 26.03% 10.96%  
Female 8.53% 33.33% 28.68% 24.81% 4.65%  
Age 
categories 
n=203 
      
0.519 
Younger than 30 
years 8.09% 16.04% 32.32% 40.05% 4.10%  
30-39 years 3.57% 33.93% 26.79% 30.36% 5.36%  
40-49 years 9.09% 34.55% 27.27% 21.82% 7.27%  
50-59 years 13.46% 36.54% 21.15% 23.08% 5.77%  
60 years or older 6.67% 26.67% 33.33% 13.33% 20.00%  
Race/ 
Ethnicity 
n=200* 
      
0.375 
Caucasian 8.38% 32.34% 24.55% 26.35% 8.38%  
Asian/Asian 
American/ 
Pacific Islander 
0.00% 25.00% 40.00% 35.00% 0.00%  
Other 15.38% 38.46% 30.77% 15.38% 0.00%  
Formal 
training 
related to 
DS or CAM 
n=204  
      
0.001 
Yes 21.43% 45.24% 11.90% 14.29% 7.14%  
No 
5.56% 28.40% 30.25% 29.01% 6.79%  
DS: dietary supplement; CAM: complementary and alternative medicine 
* The African American category was merged with the Other category because of low 
sample size 
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Table F.2 – Relationship between respondent characteristics and the overall attitudes 
toward the safety of DS 
 
 Categories 
Overall Attitude (%) 
p-value Positive 
Somewhat 
positive Neutral 
Somewhat 
negative Negative 
Gender 
n=202       
0.438 
Male 1.37% 27.40% 28.77% 31.51% 10.96%  
Female 3.88% 20.16% 36.43% 32.56% 6.98%  
Age 
categories 
n=203 
      0.638 
Younger than 
30 years 0.00% 16.00% 36.00% 40.00% 8.00%  
30-39 years 1.79% 23.21% 25.00% 39.29% 10.71%  
40-49 years 1.82% 25.45% 32.73% 32.73% 7.27%  
50-59 years 7.69% 23.08% 34.62% 25.00% 9.62%  
60 years or 
older 0.00% 20.00% 53.33% 26.67% 0.00%  
Race/ 
Ethnicity* 
n=200 
      0.080 
Caucasian 3.59% 20.96% 32.34% 33.53% 9.58%  
Asian/Asian 
American/ 
Pacific Islander 
0.00% 20.00% 25.00% 55.00% 0.00%  
Other 0.00% 38.46% 53.85% 0.00% 7.69%  
Formal 
training 
related to 
DS or CAM 
n=204  
      0.132 
Yes 7.14% 30.95% 33.33% 26.19% 2.38%  
No 2.47% 19.75% 32.72% 35.19% 9.88%  
DS: dietary supplement; CAM: complementary and alternative medicine 
* African American category was merged with Other category because of low sample size 
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Table F.3 – Raw distribution of the overall attitudes toward the clinical use of DS by 
race and formal training related to DS 
 
 Categories 
Overall Attitude Toward (%) 
Positive 
Somewhat 
positive Neutral 
Somewhat 
negative Negative 
Race/ 
Ethnicity* 
Caucasian 3.6% 21.0% 32.3% 33.5% 9.6% 
Asian/Asian 
American/ 
Pacific Islander 
0.0% 20.0% 25.0% 55.0% 0.0% 
Other 0.0% 38.5% 53.8% 0.0% 7.7% 
Formal 
training 
related to DS 
or CAM  
Yes 7.1% 31.0% 33.3% 26.2% 2.4% 
No 
2.5% 19.8% 32.7% 35.2% 9.9% 
DS: dietary supplement; CAM: complementary and alternative medicine 
* African American category was merged with Other category because of low sample size 
 
 
 
Table F.4 – Raw distribution of the overall attitudes toward the safety of DS by race 
and formal training related to DS 
 
 Categories 
Overall Attitude Toward (%) 
Positive 
Somewhat 
positive Neutral 
Somewhat 
negative Negative 
Race/ 
Ethnicity* 
Caucasian 3.6% 21.0% 32.3% 33.5% 9.6% 
Asian/Asian 
American/ 
Pacific Islander 
0.0% 20.0% 25.0% 55.0% 0.0% 
Other 0.0% 38.5% 53.8% 0.0% 7.7% 
Formal 
training 
related to DS 
or CAM  
Yes 7.1% 31.0% 33.3% 26.2% 2.4% 
No 
2.5% 19.8% 32.7% 35.2% 9.9% 
DS: dietary supplement; CAM: complementary and alternative medicine 
* African American category was merged with Other category because of low sample size 
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Figure F.1 – Backward stepwise selection of significant all two way interactions and 
covariates at alpha=0.05 for reporting to prescriber 
 
  
                                                                               
        _cons     4.445264    .261511    17.00   0.000     3.931855    4.958673
     _Ia3_7_7     .7005898   .3010481     2.33   0.020     .1095597     1.29162
     _Ia3_6_4    -.2817904   .1261372    -2.23   0.026    -.5294283   -.0341525
         a2_1    -.3257765    .073081    -4.46   0.000    -.4692521   -.1823008
     _Ia2_5_3    -.2848436   .1189597    -2.39   0.017    -.5183902   -.0512969
     _Ia3_2_2     .7319205   .2666606     2.74   0.006     .2084014     1.25544
         a2_2     .2829199   .0802503     3.53   0.000     .1253691    .4404707
     _Ia3_7_2     .6472954   .2582186     2.51   0.012       .14035    1.154241
     _Ia2_4_2     .3731772   .1177938     3.17   0.002     .1419195    .6044349
_Ioutcome_l_3      .175543   .0971795     1.81   0.071    -.0152439    .3663298
_Ioutcome_l_2     .0438097   .0993739     0.44   0.659    -.1512852    .2389047
_Ioutcome_l_1      .708289   .1029965     6.88   0.000      .506082     .910496
_Ievidence__3    -.7681562    .080373    -9.56   0.000    -.9259479   -.6103645
_Ievidence__2     .0970357   .0820167     1.18   0.237    -.0639829    .2580543
   _Itime_l_1     .0533009   .0579919     0.92   0.358    -.0605513    .1671531
_Iduration__1     .0675923   .0570529     1.18   0.237    -.0444163    .1796008
   _Iage_l_70     .0635705    .081053     0.78   0.433    -.0955561    .2226971
   _Iage_l_45    -.0901126   .0813812    -1.11   0.269    -.2498835    .0696583
                                                                               
      report1        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    2385.67968   742  3.21520172           Root MSE      =  1.5444
                                                       Adj R-squared =  0.2582
    Residual     1729.1479   725  2.38503159           R-squared     =  0.2752
       Model    656.531774    17  38.6195161           Prob > F      =  0.0000
                                                       F( 17,   725) =   16.19
      Source         SS       df       MS              Number of obs =     743
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Figure F.2 – Backward stepwise selection of significant all two way interactions and 
covariates at alpha=0.05 for reporting to the drug manufacturer 
 
  
                                                                               
        _cons     4.441455   .3317903    13.39   0.000     3.790066    5.092844
     _Ia2_7_2    -.8453017   .3188868    -2.65   0.008    -1.471358   -.2192455
     _Ia2_6_3    -.6507519   .2482497    -2.62   0.009    -1.138129   -.1633744
     _Ia3_2_2     .6879921   .2704194     2.54   0.011     .1570898    1.218894
     _Ia3_7_7      .926378   .3085697     3.00   0.003     .3205768    1.532179
     _Ia3_2_5    -1.185343   .5725435    -2.07   0.039    -2.309392   -.0612939
     _Ia3_7_8    -.5898756    .295519    -2.00   0.046    -1.170055   -.0096964
         a2_2      .197362   .0836322     2.36   0.019     .0331707    .3615532
     _Ia2_6_2    -.4789603   .2427553    -1.97   0.049    -.9555509   -.0023697
     _Ia2_4_2     .4303805   .1278653     3.37   0.001     .1793482    .6814128
         a2_1    -.3193013   .0748661    -4.26   0.000    -.4662825     -.17232
     _Ia3_7_3    -.3561325   .1429939    -2.49   0.013     -.636866   -.0753989
_Ioutcome_l_3      .051685   .0991174     0.52   0.602    -.1429077    .2462778
_Ioutcome_l_2    -.1407437   .1016334    -1.38   0.167     -.340276    .0587887
_Ioutcome_l_1     .9801716   .1047743     9.36   0.000     .7744729     1.18587
_Ievidence__3     -.503152   .0820423    -6.13   0.000     -.664222   -.3420819
_Ievidence__2     .1354989   .0839121     1.61   0.107     -.029242    .3002398
   _Itime_l_1     .0696777   .0589612     1.18   0.238    -.0460781    .1854336
_Iduration__1     .1406588   .0580666     2.42   0.016     .0266592    .2546584
   _Iage_l_70     .0794993   .0827016     0.96   0.337    -.0828651    .2418637
   _Iage_l_45    -.0909727   .0829363    -1.10   0.273    -.2537978    .0718524
                                                                               
      report2        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    2472.89098   742  3.33273717           Root MSE      =  1.5725
                                                       Adj R-squared =  0.2580
    Residual    1785.36893   722  2.47281016           R-squared     =  0.2780
       Model    687.522048    20  34.3761024           Prob > F      =  0.0000
                                                       F( 20,   722) =   13.90
      Source         SS       df       MS              Number of obs =     743
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Figure F.3 – Backward stepwise selection of significant all two way interactions and 
covariates at alpha=0.05 for reporting to the DS manufacturer 
 
  
                                                                               
        _cons     3.384227   .2832087    11.95   0.000      2.82822    3.940234
     _Ia2_6_2    -.5410885   .2385455    -2.27   0.024    -1.009411   -.0727661
     _Ia2_4_2      .533253   .1221102     4.37   0.000     .2935211    .7729848
     _Ia3_6_4     .2434671   .1218017     2.00   0.046     .0043409    .4825932
     _Ia3_1_2     .2585795   .1218956     2.12   0.034     .0192691      .49789
     _Ia3_2_2     .5397994    .262762     2.05   0.040     .0239341    1.055665
     _Ia2_7_2    -.7384843   .3094601    -2.39   0.017    -1.346029   -.1309394
     _Ia3_7_7     1.219984   .2994643     4.07   0.000     .6320636    1.807905
     _Ia2_6_3    -.7284599   .2435303    -2.99   0.003    -1.206569   -.2503511
_Ioutcome_l_3    -.0428283   .0971126    -0.44   0.659    -.2334839    .1478272
_Ioutcome_l_2    -.2001776   .0991708    -2.02   0.044    -.3948737   -.0054814
_Ioutcome_l_1     .9777807   .1026973     9.52   0.000     .7761612      1.1794
_Ievidence__3     -.408355   .0802433    -5.09   0.000     -.565892    -.250818
_Ievidence__2     .0675094   .0825388     0.82   0.414    -.0945343    .2295531
   _Itime_l_1     .0898029   .0576269     1.56   0.120    -.0233327    .2029384
_Iduration__1     .0382484   .0568348     0.67   0.501     -.073332    .1498289
   _Iage_l_70     .1289968   .0809887     1.59   0.112    -.0300035    .2879971
   _Iage_l_45    -.1368445   .0812928    -1.68   0.093    -.2964418    .0227528
                                                                               
      report3        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    2263.24092   742  3.05018991           Root MSE      =  1.5407
                                                       Adj R-squared =  0.2217
    Residual    1721.07567   725  2.37389748           R-squared     =  0.2396
       Model    542.165244    17  31.8920732           Prob > F      =  0.0000
                                                       F( 17,   725) =   13.43
      Source         SS       df       MS              Number of obs =     743
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Figure F.4 – Backward stepwise selection of significant all two way interactions and 
covariates at alpha=0.05 for reporting to FDA 
 
  
                                                                               
        _cons     2.822252   .3922896     7.19   0.000     2.052076    3.592427
     _Ia2_5_2     .4272836   .1403442     3.04   0.002     .1517482    .7028189
     _Ia3_7_7     .7715994   .3210962     2.40   0.017     .1411968    1.402002
     _Ia2_6_3    -.7922123   .2318642    -3.42   0.001    -1.247427   -.3369974
     _Ia2_4_2      .346026   .1299683     2.66   0.008     .0908615    .6011906
     _Ia3_3_3     .5754473    .216288     2.66   0.008     .1508128    1.000082
     _Ia3_3_2     .6249587    .208519     3.00   0.003     .2155769    1.034341
     _Ia3_7_3    -.5970156   .1549188    -3.85   0.000     -.901165   -.2928663
     _Ia3_3_5     1.049934   .2948636     3.56   0.000     .4710333    1.628835
     _Ia3_1_2     .4275834    .135291     3.16   0.002     .1619689    .6931979
     _Ia3_2_5    -2.088081   .5942135    -3.51   0.000     -3.25469    -.921472
         a2_1    -.2222856   .0773036    -2.88   0.004    -.3740544   -.0705168
         a2_2     .1947357   .0859074     2.27   0.024     .0260752    .3633962
     _Ia3_7_8     .6982876   .3090294     2.26   0.024     .0915756       1.305
     _Ia2_6_2    -.6840203   .2377607    -2.88   0.004    -1.150812   -.2172288
     _Ia3_2_2     .6609727   .2786717     2.37   0.018     .1138614    1.208084
     _Ia3_3_4     .6981578   .2296574     3.04   0.002     .2472753     1.14904
   _Iag45Xdu1    -.1967567   .0731006    -2.69   0.007    -.3402737   -.0532396
_Ioutcome_l_3     .1571245   .1015587     1.55   0.122     -.042264    .3565131
_Ioutcome_l_2    -.1454439   .1037584    -1.40   0.161    -.3491509    .0582632
_Ioutcome_l_1     .8937829   .1072264     8.34   0.000     .6832671    1.104299
_Ievidence__3    -.6537279   .0835109    -7.83   0.000    -.8176834   -.4897725
_Ievidence__2       .14916   .0862854     1.73   0.084    -.0202427    .3185627
   _Itime_l_1     .0900477   .0610748     1.47   0.141    -.0298594    .2099547
_Iduration__1     .1349038   .0593688     2.27   0.023      .018346    .2514615
   _Iage_l_70     .1001948   .0844249     1.19   0.236     -.065555    .2659447
   _Iage_l_45    -.1162604   .0846692    -1.37   0.170      -.28249    .0499692
                                                                               
      report4        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total     2715.0821   742   3.6591403           Root MSE      =   1.602
                                                       Adj R-squared =  0.2987
    Residual    1837.43876   716  2.56625526           R-squared     =  0.3232
       Model    877.643335    26  33.7555129           Prob > F      =  0.0000
                                                       F( 26,   716) =   13.15
      Source         SS       df       MS              Number of obs =     743
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Figure F.5 – Final linear regression model with the significant interactions and 
covariates for reporting to prescriber 
 
  
                                                                               
          rho    .40750648   (fraction of variance due to u_i)
      sigma_e    1.1840138
      sigma_u    .98193388
                                                                               
        _cons      4.75396   .3537261    13.44   0.000      4.06067    5.447251
      Ia3_7_7     .7533595   .4365946     1.73   0.084    -.1023503    1.609069
      Ia3_6_4    -.1551287   .0959554    -1.62   0.106    -.3431978    .0329405
         a2_1    -.3071474   .1057284    -2.91   0.004    -.5143713   -.0999235
      Ia2_5_3    -.2303414   .1393698    -1.65   0.098    -.5035011    .0428183
      Ia3_2_2     .2568697   .1646428     1.56   0.119    -.0658243    .5795637
         a2_2     .2467928   .1176301     2.10   0.036      .016242    .4773435
      Ia3_7_2     .6310777   .3838229     1.64   0.100    -.1212013    1.383357
      Ia2_4_2     .2021499   .0875429     2.31   0.021      .030569    .3737308
_Ioutcome_l_3     .2068004   .0812624     2.54   0.011     .0475291    .3660717
_Ioutcome_l_2     .0320458    .083362     0.38   0.701    -.1313407    .1954324
_Ioutcome_l_1     .5668594   .0880189     6.44   0.000     .3943456    .7393732
_Ievidence__3    -.8152563   .0674813   -12.08   0.000    -.9475173   -.6829953
_Ievidence__2       .12227   .0696066     1.76   0.079    -.0141564    .2586965
   _Itime_l_1      .045715   .0495211     0.92   0.356    -.0513446    .1427746
_Iduration__1      .092265   .0476449     1.94   0.053    -.0011172    .1856472
   _Iage_l_70     .0264978   .0684394     0.39   0.699     -.107641    .1606365
   _Iage_l_45    -.1003045   .0675189    -1.49   0.137    -.2326391    .0320302
                                                                               
      report1        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
corr(u_i, X)   = 0 (assumed)                    Prob > chi2        =    0.0000
                                                Wald chi2(17)      =    322.51
       overall = 0.2703                                        max =         4
       between = 0.2350                                        avg =       3.8
R-sq:  within  = 0.3289                         Obs per group: min =         1
Group variable: resid                           Number of groups   =       196
Random-effects GLS regression                   Number of obs      =       754
 
 
185 
 
 
 
 
Figure F.6 – Final linear regression model with the significant interactions and 
covariates for reporting to the drug manufacturer 
 
  
                                                                               
          rho    .48800265   (fraction of variance due to u_i)
      sigma_e    1.1325221
      sigma_u    1.1056659
                                                                               
        _cons     4.066913   .4736968     8.59   0.000     3.138484    4.995342
      Ia2_7_2    -.4760971   .2437622    -1.95   0.051    -.9538621     .001668
      Ia2_6_3    -.5184981   .3655608    -1.42   0.156    -1.234984     .197988
      Ia3_2_2      .789131    .376871     2.09   0.036     .0504774    1.527785
      Ia3_7_7     .9640744   .4707258     2.05   0.041     .0414689     1.88668
      Ia3_2_5    -.9345157   .4894942    -1.91   0.056    -1.893907    .0248752
      Ia3_7_8    -.6195219   .4660372    -1.33   0.184    -1.532938    .2938944
         a2_2     .1803343   .1294983     1.39   0.164    -.0734778    .4341463
      Ia2_6_2    -.3204673   .3579933    -0.90   0.371    -1.022121    .3811867
      Ia2_4_2     .2363833   .0967398     2.44   0.015     .0467769    .4259897
         a2_1    -.3100759   .1144795    -2.71   0.007    -.5344515   -.0857002
      Ia3_7_3    -.4093752   .2186452    -1.87   0.061    -.8379118    .0191615
_Ioutcome_l_3     .0957884   .0778254     1.23   0.218    -.0567467    .2483234
_Ioutcome_l_2    -.1741489   .0796873    -2.19   0.029    -.3303331   -.0179647
_Ioutcome_l_1     .8493167   .0839423    10.12   0.000     .6847928    1.013841
_Ievidence__3    -.5141451    .064536    -7.97   0.000    -.6406335   -.3876568
_Ievidence__2     .1147102   .0666064     1.72   0.085    -.0158359    .2452563
   _Itime_l_1     .0765672   .0473831     1.62   0.106    -.0163019    .1694364
_Iduration__1     .1461862   .0455905     3.21   0.001     .0568305    .2355418
   _Iage_l_70     .0468321   .0654121     0.72   0.474    -.0813734    .1750375
   _Iage_l_45    -.0785319   .0645129    -1.22   0.223     -.204975    .0479111
                                                                               
      report2        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
corr(u_i, X)   = 0 (assumed)                    Prob > chi2        =    0.0000
                                                Wald chi2(20)      =    288.10
       overall = 0.2731                                        max =         4
       between = 0.2861                                        avg =       3.8
R-sq:  within  = 0.2830                         Obs per group: min =         1
Group variable: resid                           Number of groups   =       197
Random-effects GLS regression                   Number of obs      =       758
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Figure F.7 – Final linear regression model with the significant interactions and 
covariates for reporting to the DS manufacturer 
 
  
                                                                               
          rho    .50164361   (fraction of variance due to u_i)
      sigma_e    1.0899349
      sigma_u    1.0935236
                                                                               
        _cons     3.576257    .318172    11.24   0.000     2.952651    4.199863
      Ia2_6_2    -.3370879     .35071    -0.96   0.336    -1.024467     .350291
      Ia2_4_2      .279204   .0946724     2.95   0.003     .0936494    .4647586
      Ia3_6_4     .1272357   .0990275     1.28   0.199    -.0668546     .321326
      Ia3_1_2     .1295388   .0950193     1.36   0.173    -.0566957    .3157732
      Ia3_2_2     .1741797   .1691147     1.03   0.303     -.157279    .5056383
      Ia2_7_2    -.4698438   .2346697    -2.00   0.045    -.9297879   -.0098997
      Ia3_7_7     1.278657   .4603846     2.78   0.005       .37632    2.180995
      Ia2_6_3    -.5030939   .3565664    -1.41   0.158    -1.201951    .1957633
_Ioutcome_l_3     .0398562   .0755327     0.53   0.598    -.1081852    .1878976
_Ioutcome_l_2    -.2053937   .0776449    -2.65   0.008    -.3575748   -.0532125
_Ioutcome_l_1     .8238365   .0815317    10.10   0.000     .6640373    .9836357
_Ievidence__3    -.4323175   .0628147    -6.88   0.000    -.5554321    -.309203
_Ievidence__2     .0224023   .0649385     0.34   0.730    -.1048748    .1496794
   _Itime_l_1     .0973126   .0461008     2.11   0.035     .0069567    .1876684
_Iduration__1     .0552729   .0442507     1.25   0.212    -.0314569    .1420028
   _Iage_l_70     .0971452   .0633599     1.53   0.125    -.0270378    .2213282
   _Iage_l_45    -.0945177   .0628182    -1.50   0.132    -.2176392    .0286037
                                                                               
      report3        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
corr(u_i, X)   = 0 (assumed)                    Prob > chi2        =    0.0000
                                                Wald chi2(17)      =    245.51
       overall = 0.2331                                        max =         4
       between = 0.2401                                        avg =       3.8
R-sq:  within  = 0.2604                         Obs per group: min =         1
Group variable: resid                           Number of groups   =       194
Random-effects GLS regression                   Number of obs      =       746
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Figure F.8 – Final linear regression model with the significant interactions and 
covariates for reporting to FDA 
 
  
                                                                               
          rho    .49478185   (fraction of variance due to u_i)
      sigma_e    1.1560481
      sigma_u    1.1440455
                                                                               
        _cons      3.55102   .5128052     6.92   0.000     2.545941      4.5561
      Ia2_5_2     .4175135   .2239319     1.86   0.062    -.0213849    .8564118
      Ia3_7_7     .8424885   .4972137     1.69   0.090    -.1320325    1.817009
      Ia2_6_3    -.6959238   .3527074    -1.97   0.048    -1.387218     -.00463
      Ia2_4_2     .2100788   .0998153     2.10   0.035     .0144444    .4057131
      Ia3_3_3    -.0051807   .2443927    -0.02   0.983    -.4841817    .4738202
      Ia3_3_2     .0702092   .2414031     0.29   0.771    -.4029321    .5433505
      Ia3_7_3    -.5817025   .2405286    -2.42   0.016     -1.05313    -.110275
      Ia3_3_5     .4392696   .2563769     1.71   0.087      -.06322    .9417591
      Ia3_1_2     .2098001   .1047826     2.00   0.045     .0044299    .4151702
      Ia3_2_5    -1.154094   .5072475    -2.28   0.023     -2.14828   -.1599067
         a2_1    -.2070594   .1191726    -1.74   0.082    -.4406334    .0265147
         a2_2     .1739574   .1348852     1.29   0.197    -.0904127    .4383276
      Ia3_7_8     .7567094   .4921475     1.54   0.124     -.207882    1.721301
      Ia2_6_2    -.5737888   .3632149    -1.58   0.114    -1.285677    .1380993
      Ia3_2_2     1.016255    .390073     2.61   0.009     .2517264    1.780785
      Ia3_3_4     .1357613   .1986269     0.68   0.494    -.2535403    .5250629
    Iag45Xdu1     -.129076   .0589242    -2.19   0.028    -.2445653   -.0135866
_Ioutcome_l_3     .1961412   .0799179     2.45   0.014      .039505    .3527774
_Ioutcome_l_2    -.1825599   .0819621    -2.23   0.026    -.3432027   -.0219172
_Ioutcome_l_1     .8306661   .0858319     9.68   0.000     .6624387    .9988935
_Ievidence__3    -.6358922   .0662324    -9.60   0.000    -.7657054   -.5060791
_Ievidence__2     .0856492   .0685186     1.25   0.211    -.0486448    .2199432
   _Itime_l_1     .0996133   .0490597     2.03   0.042      .003458    .1957686
_Iduration__1     .1290092   .0467972     2.76   0.006     .0372884      .22073
   _Iage_l_70     .0315542   .0668494     0.47   0.637    -.0994681    .1625765
   _Iage_l_45     -.068261    .066248    -1.03   0.303    -.1981048    .0615827
                                                                               
      report4        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
corr(u_i, X)   = 0 (assumed)                    Prob > chi2        =    0.0000
                                                Wald chi2(26)      =    358.40
       overall = 0.3175                                        max =         4
       between = 0.3281                                        avg =       3.8
R-sq:  within  = 0.3360                         Obs per group: min =         1
Group variable: resid                           Number of groups   =       195
Random-effects GLS regression                   Number of obs      =       750
 
 
188 
 
 
 
 
Vita 
 
 
Ali Alhammad was born in Hufof, Saudi Arabia. He was raised in Rumilah, Al 
Hassa in eastern province of Saudi Arabia. He is a Saudi resident currently living in 
Richmond, Virginia, with his wife, Wasilah Alhashim, his two daughters, Wala and 
Hawra, and his little boy Hassan. 
 
EDUCATION 
 
May 2009 – Present Virginia Commonwealth University, School of Pharmacy, 
Richmond, VA  
Doctor of Philosophy, Pharmacy Administration, to be awarded 
August 2012 
 
Jan. 2007 – May 
2009 
Virginia Commonwealth University, School of Pharmacy, 
Richmond, VA  
Masters of Sciences, Pharmacy Administration  
 
April 2006 – Dec. 
2007 
Virginia Commonwealth University, English Language Program, 
Richmond, VA. 
ESL certificate 
 
Aug. 2000 – Dec. 
2000 
King Fahad Military Medical Complex (KFMMC), Dhahran, 
Kingdom of Saudi Arabia  
Internship trainee 
 
May 2000 – Aug. 
2000 
Saudi ARAMCO Medical Services, Dhahran, Kingdom of Saudi 
Arabia 
Summer trainee 
 
 
May 1999 – Aug. 
1999 
Saudi ARAMCO Medical Services, Dhahran, Kingdom of Saudi 
Arabia 
 
 
189 
 
Summer trainee 
 
Aug. 1996 – Aug. 
2000 
King Saud University, School of Pharmacy, Riyadh, Kingdom of 
Saudi Arabia 
Bachelor of Science in Pharmaceutical sciences, awarded January. 
2001 
 
 
PROFESSIONAL EXPERIENCE 
June – Aug. 2011 Graduate health economist intern, Abbott Laboratories, Greater 
Chicago area, IL, U.S.A 
 
Aug. 2003 – March 
2006 
Grade-I hospital pharmacist, King Fahad Military Medical 
Complex (KFMMC), Dhahran, Kingdom of Saudi Arabia 
 
April 2001 – Aug. 
2003 
Grade-II hospital pharmacist, King Fahad Military Medical 
Complex (KFMMC), Dhahran, Kingdom of Saudi Arabia 
 
 
